Session feed Testing
SPECIAL INTEREST SESSIONS
ASH Clinical Practice Guidelines on Aplastic Anemia
Sunday, December 7, 2025, 4:30 p.m. - 6:00 p.m.
Hyatt - Plaza Int'l HIJK
In this session, speakers will highlight recommendations from the 2025 ASH guidelines on aplastic anemia and will discuss important considerations for the application of the recommendations in practice.
Chair:
Phillip Scheinberg, MD
Hospital A Beneficencia Portuguesa
Sao Paulo, Sao Paulo, Brazil
Speakers:
Austin G. Kulasekararaj, MD,MBBS,FRCPath,MRCP
King’s College Hospital
London, United Kingdom
Recommendations for Diagnosis of Aplastic Anemia
Kristin Ammon Shimano
UCSF Benioff Children0s Hospital
San Francisco, CA, United States
Recommendations for transplant in patients with Aplastic Anemia
Emma Groarke, MD
National Heart, Lung and Blood Institute
Bethesda, MD, United States
Recommendations for IST and medical management of Aplastic Anemia
ASH Clinical Practice Guidelines on Diagnosis of Iron Deficiency with and without Anemia
Saturday, December 6, 2025, 4:00 p.m. - 5:30 p.m.
Hyatt - Regency Ballroom OPQ
In this session, speakers will highlight recommendations from the upcoming ASH guidelines on diagnosis of iron deficiency and will discuss important considerations for the application of the recommendations in practice.
Chair:
Jacquelyn Powers, MD
Texas Children's Hematology Center
Houston, TX, United States
Speakers:
Imo Akpan, MD
Columbia University Irving Medical Center
New York, NY, United States
Ferritin, TSAT, and how low is too low: Diagnosis of iron deficiency in adults
Layla Van Doren, MD,MBA
Yale School of Medicine
New Haven, CT, United States
Menstruating individuals: Evidence-based ferritin thresholds
Michelle Sholzberg, MD
University of Toronto
Toronto, ON, Canada
Screening and defining iron deficiency in pregnant individuals
ASH Clinical Practice Guidelines on Hydroxyurea for Sickle Cell Disease
Saturday, December 6, 2025, 2:00 p.m. - 3:30 p.m.
OCCC - W311ABCD
In this session, speakers will highlight recommendations from the upcoming ASH guidelines on dosing and monitoring of hydroxyurea for SCD and will discuss important considerations for the application of the recommendations in practice.
Chair:
Venee N. Tubman, MD MMSc
Texas Children's Hospital
Houston, TX, United States
Speakers:
Aimee Hildenbrand, PhD
Nemours Children's Health
Wilmington, DE, United States
Adherence Recommendations for Hydroxyurea for SCD
Marvin Reid
Caribbean Institute for Health Research
Kingston 7, Jamaica W.I., Jamaica
Monitoring Recommendations for Hydroxyurea for SCD
Jane Hankins, MD,MS
St Jude Children's Research Hospital
Memphis, TN, United States
Dosing Recommendations for Hydroxyurea for SCD
ASH Clinical Practice Guidelines on Myelofibrosis
Saturday, December 6, 2025, 4:00 p.m. - 5:30 p.m.
OCCC - W414CD
In this session, speakers will highlight recommendations from the upcoming ASH guidelines on myelofibrosis and will discuss important considerations for the application of the recommendations in practice.
Chair:
Brady Stein, MD
Northwestern University Feinberg School of Medicine
Chicago, IL, United States
Speakers:
Anthony Michael Hunter, MD
Winship Cancer Institute of Emory University
Atlanta, GA, United States
Myelofibrosis Recommendation Highlights: Next-Generation Sequencing (NGS), Aspirin Therapy, and Iron Chelators
Douglas Tremblay, MD
Icahn School of Medicine at Mount Sinai
New York, NY, United States
Jak Inhibitors in Myelofibrosis: Recommendations for Different Risk Profiles, Symptoms, and Treatment History
Natasha Szuber
University of Montreal
Montreal, QC, Canada
Timing Transplantation and Pre-Transplant Therapy in Myelofibrosis: Recommendations for Optimal Management
ASH Clinicians in Practice Lunch: Access to Critical Drugs: The Causes, Costs, and Campaigns
Sunday, December 7, 2025, 11:15 a.m. - 12:30 p.m.
Hyatt - Florida Ballroom
Chair:
Mary-Elizabeth Percival, MD
Seattle Cancer Care Alliance
Seattle, WA, United States
Speakers:
Thomas Roades
Duke-Margolis Institute for Health Policy
Durham, NC, United States
The interactions of the pharmaceutical system and how the competing demands of different stakeholders can influence cost and shortages
Emily Mackler
YesRX
Ann Arbor, MI, United States
Combatting drug shortages with drug repository programs
Brooke Boring
Hematology/Oncology Pharmacy Association
Milwaukee, WI, United States
Advocacy at the federal and state level and how practitioners can get engaged
ASH’s SCD Initiative: 10 Years of Progress and a Look to the Future of Sickle Cell Disease Research and Care
Monday, December 8, 2025, 4:30 p.m. - 6:00 p.m.
OCCC - W230
Join us for the Center for Sickle Cell Disease Reception in W240 to follow.
Chair:
Alexis A. Thompson, MD MPH
Children's Hospital of Philadelphia
Philadelphia, PA, United States
Speakers:
Alexis A. Thompson, MD MPH
Children's Hospital of Philadelphia
Philadelphia, PA, United States
10 Years of Progress: ASH’s Sickle Cell Disease initiatives
Omar Niss, MD
Cincinnati Children's Hospital Medical Center
Cincinnati, OH, United States
Leveraging the ASH Research Collaborative SCD Research Network to Understand Underused Disease Modifying Therapies and Updates from Voxelotor?Withdrawal
Michael R DeBaun, MD, MPH
Vanderbilt University School of Medicine
Nashville, TN, United States
Findings from “Sickle Cell Trait Does Not Cause ‘Sickle Cell Crisis’ Leading to Exertion Related Death: A Systematic Review”
Catherine Chunda-Liyoka, Dr
University Teaching Hospitals - Childrens Hospitals, Ministry of Health
Lusaka, Zambia
Consortium on Newborn Screening in Africa – Diagnostic to Community Based Efforts
Robert Liem, MD
Lurie Children's Hospital
Chicago, IL, United States
ASH SCD Clinical Guidelines and Implementation Tools in Action
ASH-FDA Joint Symposium on Newly Approved Therapies I
Monday, December 8, 2025, 10:30 a.m. - 12:00 p.m.
Hyatt - Regency Ballroom S
These joint sessions, co-sponsored by the U.S. Food and Drug Administration (FDA), will feature drugs recently approved to treat hematologic disorders. FDA product-reviewers will discuss the safety and efficacy issues for the products' clinical trials and toxicity studies. The program will also include clinicians who will discuss their perspectives on the use of the products in the real-world setting. There will be ample time for questions from the audience.
back to topASH-FDA Joint Symposium on Newly Approved Therapies II
Monday, December 8, 2025, 4:30 p.m. - 6:00 p.m.
Hyatt - Regency Ballroom S
These joint sessions, co-sponsored by the U.S. Food and Drug Administration (FDA), will feature drugs recently approved to treat hematologic disorders. FDA product-reviewers will discuss the safety and efficacy issues for the products' clinical trials and toxicity studies. The program will also include clinicians who will discuss their perspectives on the use of the products in the real-world setting. There will be ample time for questions from the audience.
back to topBack to Business Breakfast
Monday, December 8, 2025, 8:00 a.m. - 9:00 a.m.
Hyatt - Florida Ballroom A
Join us at the first ever Back to Business Breakfast, a?networking-style breakfast and a closer look at ASH IGNITE, the Society’s new initiative advancing the business of innovation in hematology. A member of the ASH Business of Innovation Task Force will briefly introduce the ASH IGNITE platform, which features a Knowledge Center of expert-vetted resources and a Networking Hub connecting innovators and investors, with the goal of bringing together like-minded hematologists to create a network of innovators.
back to topBlood Advances Presents: How to Peer Review a Scientific Paper
Sunday, December 7, 2025, 11:15 a.m. - 12:15 p.m.
OCCC - W314
In this session, the Deputy Editor from Blood Advances will demystify the peer review process, covering why it matters, what makes it effective, and how you can contribute meaningfully as a reviewer. Attendees will learn practical strategies for evaluating manuscripts constructively and ethically. If you’re new to the process or looking to refine your approach, this is your crash course in becoming a trusted voice in scientific publishing.
Speaker:
Andrew Weyrich
Oklahoma Medical Research Foundation
Oklahoma City, OK, United States
Blood Advances Presents: How to Peer Review a Scientific Paper
Blood Presents: How to get Published in a Peer Review Journal
Saturday, December 6, 2025, 11:15 a.m. - 12:15 p.m.
OCCC - W314
In this candid and practical session, the Editor-in-Chief and one of the Deputy Editors from Blood will walk you through the key steps in preparing and submitting a scientific manuscript. The session will cover what editors are looking for, common pitfalls in manuscript preparation, what to expect after submission, and how to approach revisions or rejections with professionalism and purpose.
Speaker:
Andrew Roberts
Walter Eliza Hall Institute
Melbourne, Australia
Blood Presents: How to Get Published in a Peer Review Journal
Celebrating Diverse Voices: Enriching Hematology Lunch
Monday, December 8, 2025, 12:00 p.m. - 1:30 p.m.
Hyatt - Florida Ballroom A
This is a community-building and networking event for members from an expansive and inclusive group of communities attending the meeting. The event is hosted by the Committee on Advancing Excellence and Population Health and aims to create space for these communities to learn more about the differing experiences and needs across communities and create a sense of belonging and allyship. This year’s event will include inspiring remarks from a fellow member and networking opportunities throughout.
back to topCenter for Sickle Cell Disease Initiatives Reception
Monday, December 8, 2025, 6:00 p.m. - 8:00 p.m.
OCCC - W240
Join us for a special evening reception celebrating ASH’s 10-year commitment to improving the lives of individuals living with sickle cell disease. This milestone event honors a decade of transformative progress, collaboration, and advocacy. Guests will have the opportunity to network with leaders in hematology and sickle cell research. Whether you’ve been part of this movement from the beginning or are newly engaged, we welcome you to celebrate this momentous occasion with us.
back to topEarly Faculty Career Development Session
Sunday, December 7, 2025, 4:30 p.m. - 6:00 p.m.
Hyatt - Regency Ballroom S
This year, we will focus on how to be successful in your first 'real' job. Curated faculty speakers representing diverse job profiles will share their journey and advice on this topic. Strategies to develop a productive clinical or laboratory based research program, finding success as an practicing clinician and a clinical educator will be discussed. The speakers will then join a panel discussion on pathways to sustained success and job satisfaction where they will also address questions from the audience.
Chair:
Hetty Carraway, MD, MBA
Cleveland Clinic
Cleveland, OH, United States
Speakers:
Courtney Jones, PhD
Cincinnati Children's Hospital
Cincinnati, OH, United States
Developing a Productive Research Program (How to Set up a New Laboratory) - Part 1
Alexey V. Danilov, MD, PhD
City of Hope National Medical Center
Duarte, CA, United States
Developing a Productive Research Program (How to Set up a New Laboratory) - Part 2
Peter Kouides, MD
University of Rochester
Rochester, NY, United States
Developing a Focused Area of Clinical Expertise - Part 1
Usha S Perepu
UT Health San Antonio
San Antonio, TX, United States
Developing a Focused Area of Clinical Expertise - Part 2
Courtney Jones, PhD
Cincinnati Children's Hospital
Cincinnati, OH, United States
Setting Yourself Up for Sustained Success - Panelist 1
Alexey V. Danilov, MD, PhD
City of Hope National Medical Center
Duarte, CA, United States
Setting Yourself Up for Sustained Success - Panelist 2
Peter Kouides, MD
University of Rochester
Rochester, NY, United States
Setting Yourself Up for Sustained Success - Panelist 3
Usha S Perepu
UT Health San Antonio
San Antonio, TX, United States
Setting Yourself Up for Sustained Success - Panelist 4
Grassroots Network Lunch
Saturday, December 6, 2025, 11:15 a.m. - 12:15 p.m.
Hyatt - Florida Ballroom
The ASH Grassroots Network Lunch provides a forum for interested members to learn how they can participate in ASH’s advocacy efforts, communicate with Congress and their elected officials, become effective advocates for hematology, and discuss the Society’s legislative and regulatory priorities. An overview of the Society’s 2025 advocacy accomplishments and a preview of the Society’s 2026 advocacy agenda will also be provided. This year’s event will also highlight ASH’s expanded advocacy and the Fight4Hematology campaign with a panel of ASH stakeholders who have advocated in different ways, sharing their efforts and stories.
Chair:
Bart Scott
Hematology Inclusion Pathway (HIP) Oral Presentations – Classical Hematology
Saturday, December 6, 2025, 6:30 p.m. - 8:00 p.m.
Hyatt - Florida Ballroom C
Join us for this special session highlighting the research of ASH Hematology Inclusion Pathway (HIP) awardees. The HIP initiative is a comprehensive, 13-year longitudinal career pathway designed to ensure that the field of hematology reflects and serves the diverse world we live in. The session will feature oral scientific presentations from current program awardees, highlighting their innovative work and contributions to the field, with a focus on Classical Hematology.
Following the presentations, we welcome you to connect with the HIP community and celebrate our awardees and their mentors at a networking reception.
Moderators:
Imo Akpan
Satiro De Oliveira
Hematology Inclusion Pathway (HIP) Oral Presentations – Health Services Outcomes
Saturday, December 6, 2025, 6:30 p.m. - 8:00 p.m.
Hyatt - Plaza Int'l F
Join us for this special session highlighting the research of ASH Hematology Inclusion Pathway (HIP) awardees. The HIP initiative is a comprehensive, 13-year longitudinal career pathway designed to ensure that the field of hematology reflects and serves the diverse world we live in. The session will feature oral scientific presentations from current program awardees, highlighting their innovative work and contributions to the field, with a focus on Health Services Outcomes.
Following the presentations, we welcome you to connect with the HIP community and celebrate our awardees and their mentors at a networking reception.
Moderators:
Margo Rollins
Joanna Robles
Hematology Inclusion Pathway (HIP) Oral Presentations - Malignant Hematology I
Saturday, December 6, 2025, 6:30 p.m. - 8:00 p.m.
Hyatt - Florida Ballroom A
Join us for this special session highlighting the research of ASH Hematology Inclusion Pathway (HIP) awardees. The HIP initiative is a comprehensive, 13-year longitudinal career pathway designed to ensure that the field of hematology reflects and serves the diverse world we live in. The session will feature oral scientific presentations from current program awardees, highlighting their innovative work and contributions to the field, with a focus on Malignant Hematology.
Following the presentations, we welcome you to connect with the HIP community and celebrate our awardees and their mentors at a networking reception.
Moderators:
Yolanda Fortenberry
Nada Hamad
Speakers:
Cilomar Martins de Oliveira Filho
Beth Israel Deaconess Medical Center
Boston, MA, United States
Risk stratification of patients with TP53-mutated myeloproliferative neoplasms
Jessica Maria Stempel, MD, MHS
Yale School of Medicine
New Haven, CT, United States
Impact of metformin on outcomes in older adults with classical myeloproliferative neoplasms
Hematology Inclusion Pathway (HIP) Oral Presentations – Malignant Hematology II
Saturday, December 6, 2025, 6:30 p.m. - 8:00 p.m.
Hyatt - Florida Ballroom B
Join us for this special session highlighting the research of ASH Hematology Inclusion Pathway (HIP) awardees. The HIP initiative is a comprehensive, 13-year longitudinal career pathway designed to ensure that the field of hematology reflects and serves the diverse world we live in. The session will feature oral scientific presentations from current program awardees, highlighting their innovative work and contributions to the field, with a focus on Malignant Hematology.
Following the presentations, we welcome you to connect with the HIP community and celebrate our awardees and their mentors at a networking reception.
Moderators:
Anita D'Souza, MD
Randolph Lyde
Speaker:
Kevin Robert Reyes, MD
University of California, San Francisco
San Francisco, CA, United States
The Role of Immunogenomics on the Sequencing of T-cell Redirection Therapies in Relapsed/Refractory Multiple Myeloma
Hematology Inclusion Pathway Reception
Saturday, December 6, 2025, 8:00 p.m. - 9:00 p.m.
Hyatt - Plaza Int'l DE
Join the HIP community to connect, network, and celebrate the achievements of our awardees and their mentors at this special reception following the oral presentations. This event offers an opportunity to build connections across the HIP network, engage with colleagues who share a commitment to fostering diversity in hematology, and recognize the exceptional work of program participants.
back to topHow Can Community-Based and Academic Hematologists Foster Clinical Trial Participation as Part of Patient Care?
Sunday, December 7, 2025, 9:30 a.m. - 11:00 a.m.
Hyatt - Plaza Int'l HIJK
Patients often learn about clinical trials from their healthcare providers. However, the barriers to trial participation include: patients not being offered trials; physicians not having the capacity to effectively navigate clinicaltrials.gov and enroll patients; and community-based physicians are often not engaged (or engaged early enough to make a meaningful impact) in the clinical trial life cycle. This session will (1) address barriers that practicing hematologists face offering trials to patients, (2) provide practical solutions to overcome these barriers and (3) highlight best practices to engage patients and increase participation in trials.
Speakers will consist of a mix of practicing hematologists as well as other stakeholders in the clinical trial enterprise sharing their perspectives on the issue. The session will conclude with the speakers providing practical tactics that the audience can take to enhance access, inclusivity, and ultimately representation in hematology trials.
Chair:
Leonard Valentino
Rush University Medical Center
New York, NY, United States
Speakers:
Leonard Valentino
Rush University Medical Center
New York, NY, United States
Challenges to Clinical Trial Participation
Lanre Tunji-Ajayi, MS
Sickle Cell Awareness Group of Ontario
Pickering, ON, Canada
Patient Perspective
John M. M. Burke, MD
Rocky Mountain Cancer Centers
Aurora, CO, United States
Engagement of Community Physicians in Clinical Trials
Fabio Dennstaedt
University Hospital and University of Bern
Bern, Switzerland
Moving Patients to Participants in Hematology Clinical Trials
Stephanie Valer Seremetis, MD
Novo Nordisk A/S
Plainsboro, NJ, United States
Industry Perspective
Alysha Croker
Health Canada
Ottawa, ON, Canada
Government Perspective
Jeffrey Keefer, MD,PhD
IQVIA
Keswick, VA, United States
Contract Research Organization Perspective
Michelle Feige
Accreditation of Human Research Protection Programs (AAHRPP)
Washington, DC, United States
Institutional Review Board Perspective
Joint Session: Advancing Hematology Through Artificial Intelligence
Saturday, December 6, 2025, 4:00 p.m. - 5:30 p.m.
Hyatt - Regency Ballroom S
Artificial intelligence (AI) is poised to
transform hematology - from decoding the biology of hematopoiesis to guiding
real-time treatment decisions. This session will unite innovators spanning
discovery science to bedside care, delivering an evidence-based roadmap of
where AI is today and where it is headed.
Specifically, the session will address the following goals: (1) contextualizing the AI revolution in biomedicine; (2) showcasing state-of-the-art foundation models that refine cell-state inference in health and disease; (3) revealing AI-driven diagnostic platforms already reshaping laboratory hematology; and (4) charting practical, ethical pathways for responsible clinical deployment.
Attendees will leave with a clear conceptual framework linking foundational AI principles to concrete applications in hematology; actionable examples of how large-scale models boost biological insight and diagnostic accuracy; and a realistic grasp of implementation challenges. By tracing the arc from algorithm to patient, the session will empower participants to critically appraise emerging technologies, identify collaboration opportunities, and craft informed research or adoption strategies that ultimately can improve patient care.
Speakers:
Shannon McWeeney
OHSU
Portland, OR, United States
General AI: The AI Revolution in Healthcare: From Hype to Real-World Impact
Bo Wang
University of Toronto
Toronto, ON, Canada
Basic and Translational AI: Mapp
Sanam Loghavi, MD
The University of Texas MD Anderson Cancer Center
Houston, United States
Diagnostics and Implementation:
Karandeep Singh
University of California San Diego
San Diego, CA, United States
Clinical Applications of AI: AI at the Bedside: Real-World Clinical Applications
Leveraging Genetic Diversity in Preclinical Discovery to Guide Precision Medicine
Saturday, December 6, 2025, 9:30 a.m. - 10:45 a.m.
OCCC - W314
Consideration for variability in the
constitutional DNA in medical research presents a unique opportunity to uncover
novel biology, identify population-specific risk factors, and develop tailored
therapies. By embracing the genetic and environmental variations across
populations, we can unlock new avenues for innovation. While the clinical
impact of variations in the somatic genetic profile, clinical presentation and
survival prognostications are recognized, there is an unmet need to better
understand the underlying biology of sometimes contrasting genotype-phenotype
associations originating from varying germline genetic ancestries. This is
caused by difficulties of biologically faithful functionalization approaches,
and also limitations in the availability of suitable model organisms.
This session will present examples of bench-to-bedside translations, new model systems and basic research tools that have broad applicability for both basic and translational researchers. It may catalyze collaborations between translational researchers and basic scientists. In addition, the session aims to bridge the gap between clinical practice and basic research by exploring the critical role of genetic variation as a proxy for advancing precision medicine.
Attendees of the session will leave with an appreciation for the importance of considering genetic variation in research and cross-disciplinary partnerships to drive meaningful advances in patient treatment and survival.
Speakers:
Kellie Machlus, PhD
Boston Children's Hospital
Boston, United States
Discovery Based on Population Structure: How to Faithfully Understand and Functionalize Novel Treatments
Adam J de Smith
University of Southern California Keck School of Medicine
Los Angeles, CA, United States
Decoding Bias in Disease Risk: The Role of Ancestry and Genomic Variant Clustering
Jesse Boehm Jr
MIT
Cambridge, MA, United States
Moving Towards Precision Medicine: Influence of Germline and Ancestry on Preclinical Target Discovery
Leveraging Real-World Data in Multiple Myeloma for Regulatory Purposes
Sunday, December 7, 2025, 9:30 a.m. - 11:00 a.m.
OCCC - West Hall E1
Real-world data (RWD) programs have become a vital resource to researchers to transform medicine. RWD provide large volumes of data that allow researchers to precisely target specific patient populations for research and to tailor new treatments and care regimens to improve patient outcomes. This 90-minute session, hosted by the ASH Research Collaborative Multiple Myeloma Research Network, will explore how various programs are leveraging RWD to drive real-world evidence generation and impactful research for regulatory purposes and advancing care.
Chair:
Saad Z. Usmani, MD
Memorial Sloan Kettering Cancer Center
New York, NY, United States
Speakers:
Saad Z. Usmani, MD
Memorial Sloan Kettering Cancer Center
New York, NY, United States
Welcome and Opening Remarks
Shaji Kumar, MD
Mayo Clinic
Rochester, MN, United States
Using Real-World Data to Accelerate Research on Multiple Myeloma Patient Cohorts: Lessons from the ASH RC Multiple Myeloma Data Hub
Othman Salim Akhtar, MD, MBBS
Medical College of Wisconsin
Milwaukee, WI, United States
Using Real-World Data to Accelerate Research on Multiple Myeloma Patient Cohorts: Lessons from CIBMTR
Nicole Gormley, MD
Food and Drug Administration
Silver Spring, MD, United States
Using Real-World Data to Accelerate Research on Multiple Myeloma Patient Cohorts: RWE Guidance from the FDA Perspective
Edward Laane, MD, PhD
European Medicines Agency (EMA)
Tartu, Estonia
Using Real-World Data to Accelerate Research on Multiple Myeloma Patient Cohorts: RWE Guidance from the EMA Perspective
Sushmita Sen, PhD
Roche
Basel, Switzerland
Using Real-World Data to Accelerate Research on Multiple Myeloma Patient Cohorts: RWE Considerations from the Industry Perspective
Saad Z. Usmani, MD
Memorial Sloan Kettering Cancer Center
New York, NY, United States
Panel Discussion and Audience Q&A
Leveraging Real-World Data in Sickle Cell Disease to Identify and Study Specific Cohorts of Interest
Saturday, December 6, 2025, 9:30 a.m. - 11:00 a.m.
OCCC - W308
Real-world data (RWD) programs have become a vital resource for researchers to transform medicine. RWD provides large volumes of data that allow researchers to precisely target specific patient populations and tailor new treatments and care regimens to improve patient outcomes. This 90-minute session, hosted by the ASH Research Collaborative SCD Research Network, will explore how various RWD programs allow researchers to use RWD to identify specific patient populations of interest and drive impactful research.
Chair:
Charles Abrams, MD
U Penn
Philadelphia, PA, United States
Speakers:
Charles Abrams, MD
U Penn
Philadelphia, PA, United States
Welcome and Opening Remarks
Biree Andemariam, MD
University of Connecticut
West Hartford, CT, United States
Using Machine Learning to Analyze Sickle Cell Disease Hospital Utilization and Chronic Kidney Disease
Patty Steinert, PhD, MBA
Medical College of Wisconsin
Milwaukee, WI, United States
Case Studies for Collaborative Research: Using RWD to Accelerate Research on SCD Patient Cohorts: Using CIBMTR to Track Patients on Gene Therapy for Long-Term Safety and Efficacy
Jeffrey Lebensburger, DO
University of Alabama at Birmingham
Birmingham, AL, United States
Case Studies for Collaborative Research: Using RWD to Accelerate Research on SCD Patient Cohorts: Using RWD to Develop a Framework to Support SCD Treatment Research
Charles Abrams, MD
U Penn
Philadelphia, PA, United States
Panel Discussion and Audience Q&A
Julie Kanter, MD
University of Alabama at Birmingham
Birmingham, AL, United States
Case Studies for Embedding Data Quality with Cohort Identification Studies for More Effective SCD Research Case: Using Multiple RWD Sources to Identify People with SCD Eligible for Novel Therapies
Charles Abrams, MD
U Penn
Philadelphia, PA, United States
Panel Discussion and Audience Q&A
LGBTQIA+ Community Networking Brunch
Sunday, December 7, 2025, 11:00 a.m. - 12:30 p.m.
Hyatt - Plaza Int'l DEFG
This is a community-building and networking event for members of the LGBTQIA+ community attending the meeting. The event is hosted by the Committee on Advancing Excellence and Population Health and aims to create a sense of belonging and allyship. This year’s event will include breakout group discussion on mentorship, community building, and career advancement followed by speed networking.
back to topMedical Educators' Symposium
Sunday, December 7, 2025, 7:00 a.m. - 9:00 a.m.
Hyatt - Plaza Int'l DEFG
The ASH 2025 Medical Educators Symposium will be focused on cultural evolutions, both for academic medical practice and trainee education. Medical education and patient care are rapidly transforming from the perspective of inclusivity, cultural humility, and mixed methods of teaching. Come hear from educational experts about how to better engage trainees through revolutionary multimedia approaches as well. Regardless of your training level or faculty rank, come join the conversation and share your perspectives. Everyone's voice matters!
Chair:
Alexander Boucher, MD
University of Minnesota
Minneapolis, MN, United States
Speakers:
Robert Stern, MD
Dana-Farber Cancer Institute
Boston, MA, United States
General Session 1: The Evolving Landscape of Cultural Terminology in Hematology Part 1
Laura DeCastro, MD
University of Pittsburgh Medical Center
Pittsburgh, PA, United States
General Session 1: The Evolving Landscape of Cultural Terminology in Hematology Part 2
Jean M. Connors, MD
Harvard Medical School
Boston, MA, United States
General Session 2: Tips and Tricks to Efficiently Handle Knowledge Gathering Part 1
Jori May, MD
University of Alabama at Birmingham
Birmingham, AL, United States
General Session 2: Tips and Tricks to Efficiently Handle Knowledge Gathering Part 2
Ronak Mistry, DO
University of Pennsylvania
Philadelphia, PA, United States
General Session 3: Content Creation as Medical Educators Part 1
Jonaphine Mata, MD
Johns Hopkins University
Baltimore, MD, United States
General Session 3: Content Creation as Medical Educators Part 2
Alexander Boucher, MD
University of Minnesota
Plymouth, MN, United States
General Session Q&A
Ronak Mistry, DO
University of Pennsylvania
Philadelphia, PA, United States
Breakout 1: Multimedia Integration into Educational Curricula - Facilitator A
Jonaphine Mata, MD
Johns Hopkins University
Baltimore, MD, United States
Breakout 1: Multimedia Integration into Educational Curricula - Facilitator B
Marina Heskel, MD
University of California San Francisco
San Francisco, CA, United States
Breakout 2: Mixed Methods Educational Strategies for All Learners - Facilitator A
Reed E. Drews, MD
Beth Israel Deaconess Medical Center
Boston, MA, United States
Breakout 2: Mixed Methods Educational Strategies for All Learners - Facilitator B
Robert Stern, MD
Dana-Farber Cancer Institute
Boston, MA, United States
Breakout 3: Cultural Humility in Hematology Care - Facilitator A
Rohini Jain, MD
University of California San Francisco
San Francisco, CA, United States
Breakout 3: Cultural Humility in Hematology Care - Facilitator B
Sana Saif Ur Rehman, MD
Washington University in St Louis
Saint Louis, MO, United States
Breakout 4: Innovation in Education for the Current Generation - Facilitator A
Thomas Deloughery, MD
Oregon Health and Science Univ.
Portland, OR, United States
Breakout 4: Innovation in Education for the Current Generation - Facilitator B
Simulcast of Announcement of Awards and Plenary Scientific Session
Sunday, December 7, 2025, 1:30 p.m. - 4:00 p.m.
OCCC - W314
If you are unable to make it to the Marquee Session Room (OCCC - West Hall D2) in time for the start of the Announcement of Awards and/or Plenary Scientific Session, take advantage of this opportunity as the sessions will be shown in this room.
back to topSimulcast of Announcement of Awards and Plenary Scientific Session
Sunday, December 7, 2025, 1:30 p.m. - 4:00 p.m.
Hyatt - Regency Ballroom S
If you are unable to make it to the Marquee Session Room (OCCC - West Hall D2) in time for the start of the Announcement of Awards and/or Plenary Scientific Session, take advantage of this opportunity as the sessions will be shown in this room.
back to topTo, Through and Thereafter: Guiding Sickle Cell Disease Patients Considering Gene Therapy
Sunday, December 7, 2025, 9:30 a.m. - 11:00 a.m.
OCCC - W311ABCD
In 2023, the Food & Drug Administration approved the first gene therapies for the treatment of sickle cell disease. However, despite these advancements, only a small number of impacted individuals have received gene therapy, despite over 100,000 people living with the disease in the United States. The ASH Health Equity Task Force is hosting this special-interest session to highlight important considerations for providers and administrators to consider as they guide patients and patient representatives in accessing, navigating through, and after care for gene therapy.
This session is 90 minutes in duration. The first hour will consist of a facilitated panel discussion to educate hematologists on the nuances of understanding (1) key considerations to share with patients in determining if gene therapy is a viable treatment for them, (2) helping patients understand what they can expect and how they may need to prepare, if they proceed with gene therapy, and (3) critical preparation for patients and their caregivers to optimize their post treatment recovery and continuity of care for the long term. Following the panel discussion there will be 30 minutes for questions from the audience. The panel will be composed of 3 hematologists and 2 lived experience experts (LEEs) who will share their expertise and perspective for how to support and guide patients through each of the three stages of the process:
1. To Gene Therapy – which will focus on hematologists who are selecting and referring patients for gene therapy and also facing insurance approval challenges.
2. Through Gene Therapy – which will focus on physicians performing gene therapy and involved in day-to-day management of complications, etc.
3. Thereafter, Gene Therapy – which will focus on physicians involved in post-gene therapy management.
Chair:
Titilope Fasipe Jr, MD, PhD
Baylor College of Medicine
Houston, TX, United States
Speakers:
Alexis Leonard, MD
St. Jude Children's Research Hospital
Memphis, TN, United States
To Gene Therapy
Alexander Ngwube, MD
Baylor College of Medicine/Texas Children's Hospital
Houston, TX, United States
Through Gene Therapy
Andrew Campbell, MD
Children's National Hospital
Washington, DC, United States
Thereafter Gene Therapy
Rae Blaylark
Sickle Cell Foundation of MN
Minneapolis, MN, United States
Lived Experience Expert
Olujimi Olaghere
Sugarloaf Capital
Atlanta, GA, United States
Lived Experience Expert
Training Program Directors Workshop
Friday, December 5, 2025, 9:00 a.m. - 12:00 p.m.
SeaWorld - Ports of Call 1
The goal of the 2025 Training Program Directors Workshop is to look forward and determine how hematology-oncology fellowships can innovate and change in order to improve our programs and meet the needs of our future fellows. Through learning about innovations within other fellowship programs, understanding how professionalism expectations can change to meet the contemporary fellow, and considering the career trajectories for med-peds trained residents, we hope that the session will encourage program directors to assess their own programs and consider opportunities for improvement/innovation.
Enter through SeaWorld's Ports of Call VIP Gates for all ASH Activities at the park.
Chair:
Robert Stern, MD
Dana-Farber Cancer Institute
Boston, MA, United States
Speakers:
Rakhi P. Naik Jr, MD, MHS
Johns Hopkins University School of Medicine
Baltimore, MD, United States
Innovations Large and Small in Hematology/Oncology Fellowship Training Part 1
Lisa Pei Chu I, MD
University of Colorado Anschutz Medical Center
Aurora, CO, United States
Innovations Large and Small in Hematology/Oncology Fellowship Training Part 2
Jennifer Yui Jr, MD,MSc
Johns Hopkins University School of Medicine
Baltimore, MD, United States
Innovations Large and Small in Hematology/Oncology Fellowship Training Part 3
Yannis Valtis, MD
Memorial Sloan Kettering Cancer Center
New York, NY, United States
Med Peds Path to Heme/Onc Training Part 1
John Molina, MD, MEd
CCF
Shaker Heights, OH, United States
Med Peds Path to Heme/Onc Training Part 2
Jennifer Kesselheim, MD,MEd
Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Boston, MA, United States
Professionalism Part 1
Jennifer Cooperrider, MD
University of Chicago
Chicago, IL, United States
Professionalism Part 2
Treating Fairly Rounds Lunch
Sunday, December 7, 2025, 11:30 a.m. - 12:30 p.m.
Hyatt - Manatee Spring
The Treating Fairly Rounds Lunch session will
- Introduce the role of language (and cultural diversity) in the delivery of health care for non-English speaking populations
- Discuss the impact of language barrier on the utilization of old and novel therapies, patient compliance, safety, and disease outcomes
- Present potential solutions to overcome some of the challenges posed by language barriers and improve healthcare quality and patient outcomes.
Speakers:
Rahma Warsame, MD
Mayo Clinic
Rochester, MN, United States
Healthcare Access to Non-English Speaking Populations - Presenter 1
Cesar Rodriguez Valdes, MD
Icahn School of Medicine at Mount Sinai
New York, NY, United States
Healthcare Access to Non-English Speaking Populations - Presenter 2
Updated ASH Clinical Practice Guidelines on Acute Myeloid Leukemia (AML) in Older Adults
Sunday, December 7, 2025, 9:30 a.m. - 11:00 a.m.
OCCC - W414CD
In this session, speakers will highlight recommendations from the updated ASH guidelines on AML in older adults and will discuss important considerations for the application of the recommendations in practice.
Chair:
Mikkael Sekeres, MD
Sylvester Comprehensive Cancer Center, University of Miami
Miami, FL, United States
Speakers:
Kah Poh (Melissa) Loh, MD, MS
University of Rochester Medical Center
Rochester, NY, United States
Treatment Options for Older Adults with AML: Recommendations on Low-Dose Cytarabine, Azacitidine, and Decitabine Regimens as Monotherapy or Combinations
Luca Malcovati, MD
University of Pavia and IRCCS S. Matteo Hospital Foundation
Pavia, PV, Italy
Treatment Options for Older Adults with AML and IDH1/IDH2 Mutations: Recommendations on HMA Monotherapy, Combinations with Venetoclax, and Targeted Therapies
Maria R. Baer, MD
University of Maryland
Baltimore, MD, United States
Recommendations for Treatment for Older Adults with AML and FLT3 Mutations
Updated ASH Clinical Practice Guidelines on Immune Thrombocytopenia (ITP) in Adults
Sunday, December 7, 2025, 4:30 p.m. - 6:00 p.m.
OCCC - W304EFGH
In this session, speakers will highlight recommendations from an upcoming revision to the ASH ITP guidelines focused on second-line therapies. Speakers will also discuss important considerations for the application of the recommendations in practice
Chair:
Douglas Cines Sr, Prof
University of Pennsylvania
Philadelphia, PA, United States
Speakers:
Sylvain Audia, MD, PhD
University of Bourgogne
Dijon, Bourgogne, France
Should adults with primary ITP requiring initial treatment receive steroids alone or steroids in combination with an additional agent? Recommendations from the ASH Guidelines
Camila Masias, MD,MPH
Miami Cancer Institute
Miami, FL, United States
What treatment should be given to adults with primary ITP who require therapy beyond steroids? Recommendations from the ASH Guidelines
Donald Arnold, MD
McMaster University
Hamilton, ON, Canada
Considerations on the Role of Splenectomy and Switching TPOs After Treatment Failure
Women in Hematology Networking Event
Monday, December 8, 2025, 7:30 p.m. - 9:30 p.m.
Hyatt - Plaza Int'l DEFG
This popular annual networking event will provide a space where all can gather and connect with peers and potential mentors. The panel will explore the theme of transitions—an important and relevant topic that offers valuable, actionable insights for navigating change in both personal and professional life. Light refreshments available during the panel; please join us for a post-panel reception with heavy hors d’oeuvres.
Blood Journals Studio
Hemato-Logic: How to Share Your Cases with the ASH Image Bank and Blood Work
Saturday, December 6, 2025, 2:00 p.m. - 2:45 p.m.
OCCC - West Halls B3-B4
Join this studio session to learn how to contribute to ASH Image Banks’s extensive online image library. Whether you're a student, educator, author, or clinician, this session offers practical guidance on submitting high-quality hematologic images and case descriptions that highlight key microscopic features. Discover how to share your work effectively and make a lasting educational impact through ASH’s peer-reviewed Image Bank and Blood Work resources.
Seating is limited and available on a first-come, first-served basis. This session will be held at the Blood Journals Studio, which is located in the ASH Poster Hall (Orange County Convention Center, West Hall B3-B4).
Speaker:
Sanam Loghavi
, MD
The University of Texas MD Anderson Cancer Center
Houston,
United States
Hemato-Logic: How to Share Your Cases with the ASH Image Bank and Blood Work
How to Create a Strong Visual Abstract
Saturday, December 6, 2025, 3:00 p.m. - 4:00 p.m.
OCCC - West Halls B3-B4
Want to make your research more accessible, memorable, and shareable? Much like a traditional abstract, a visual abstract captures the essence of your study but in a format that’s easier to quickly interpret. It simplifies complex methodologies and highlights major outcomes at a glance, making your work more impactful across audiences, especially if shared on social media or in a presentation. In this session, you’ll gain practical skills and insights to design compelling visual abstracts that bring your research to life.
This session will be held at the Blood Journals Studio, which is located in the ASH Poster Hall (Orange County Convention Center, West Hall B3-B4).Speaker:
Mario Cazzola
University of Pavia
Pavia,
Italy
How to Create a Strong Visual Abstract
Meet the Journal Editors: Blood
Sunday, December 7, 2025, 4:00 p.m. - 4:30 p.m.
OCCC - West Halls B3-B4
Join us for the opportunity to meet with editors of Blood, ASH’s flagship journal. This journal provides an international forum for the publication of original articles describing basic laboratory, translational, and clinical investigations in hematology. Whether you're curious about how decisions get made, want to sharpen your peer review skills, or are exploring how to share your research more effectively, these sessions offer real access and real insight—from the people shaping the future of hematology literature.
Seating is limited and available on a first-come, first-served basis. This session will be held at the Blood Journals Studio, which is located in the ASH Poster Hall (Orange County Convention Center, West Hall B3-B4).
back to topMeet the Journal Editors: Blood Advances
Saturday, December 6, 2025, 1:30 p.m. - 1:55 p.m.
OCCC - West Halls B3-B4
This dynamic session offers a chance to engage with the editors of ASH’s leading open-access hematology journal, Blood Advances. Whether you're curious about how decisions get made, want to sharpen your peer review skills, or are exploring how to share your research more effectively, these sessions offer real access and insight.
Seating is limited and available on a first-come, first-served basis. This session will be held at the Blood Journals Studio, which is located in the ASH Poster Hall (Orange County Convention Center, West Hall B3-B4).
Speaker:
Andrew Weyrich
Oklahoma Medical Research Foundation
Oklahoma City,
OK, United States
Meet the Journal Editors: Blood Advances
Meet the Journal Editors: Blood Global Hematology
Monday, December 8, 2025, 12:00 p.m. - 12:20 p.m.
OCCC - West Halls B3-B4
This engaging session provides the opportunity to connect with editors of ASH’s open-access journal focused on global hematologic challenges. This session will provide an opportunity to learn about how to publish in the journal, gain insight into the peer review process, and learn about the journal's editorial scope.
Seating is limited and available on a first-come, first-served basis. This session will be held at the Blood Journals Studio, which is located in the ASH Poster Hall (Orange County Convention Center, West Hall B3-B4).
Speaker:
Jorge Cortes
, MD
Georgia Cancer Center at Augusta University
Augusta,
GA, United States
Meet the Journal Editors: Blood Global Hematology
Meet the Journal Editors: Blood Immunology & Cellular Therapy
Saturday, December 6, 2025, 8:30 a.m. - 8:55 a.m.
OCCC - West Halls B3-B4
This lively session provides the opportunity to meet with editors of Blood Immunology & Cellular Therapy, one of ASH’s newest journals. This journal is focused on publishing original research on basic, translational, and clinical studies focused on cellular and non-cellular immunotherapies for hematological disorders and their underlying immunology. Whether you're curious about how editorial decisions are made, want to sharpen your peer review skills, or are exploring how to share your research more effectively, these sessions offer real access and insight.
Seating is limited and available on a first-come, first-served basis. This session will be held at the Blood Journals Studio, which is located in the ASH Poster Hall (Orange County Convention Center, West Hall B3-B4).
Speaker:
Caron Jacobson
, MD, MMSc
Dana Farber Cancer Institute
New York,
NY, United States
Meet the Journal Editors: Bloo
Meet the Journal Editors: Blood Neoplasia
Sunday, December 7, 2025, 9:15 a.m. - 9:45 a.m.
OCCC - West Halls B3-B4
This interactive session provides the opportunity to meet with editors of Blood Neoplasia, one of ASH’s newer journals. This journal provides an international forum, publishing original research on basic, translational, and clinical studies of hematologic malignancies and related disorders, including blood cancers, immune dysregulation, and precursor conditions. Whether you're curious about how editorial decisions get made, want to sharpen your peer review skills, or are exploring how to share your research more effectively, these sessions offer real access and insight.
Seating is limited and available on a first-come, first-served basis. This session will be held at the Blood Journals Studio, which is located in the ASH Poster Hall (Orange County Convention Center, West Hall B3-B4).
Speaker:
Maria E. Figueroa
University of Miami Miller School of Medicine
Miami,
FL, United States
Meet the Journal Editors: Blood Neoplasia
Meet the Journal Editors: Blood Red Cells & Iron
Monday, December 8, 2025, 10:00 a.m. - 10:30 a.m.
OCCC - West Halls B3-B4
This engaging session provides the opportunity to meet with editors of Blood Red Cells & Iron, one of ASH’s newest journals. Whether you're curious about how editorial decisions get made, want to sharpen your peer review skills, or are exploring how to share your research more effectively, these sessions offer real access and insight.
Seating is limited and available on a first-come, first-served basis. This session will be held at the Blood Journals Studio, which is located in the ASH Poster Hall (Orange County Convention Center, West Hall B3-B4).
Speaker:
Patrick Gallagher
, MD
Nationwide Children's Hospital
Columbus,
OH, United States
Meet the Journal Editors: Bloo
Meet the Journal Editors: Blood Vessels, Thrombosis & Hemostasis
Saturday, December 6, 2025, 9:00 a.m. - 9:30 a.m.
OCCC - West Halls B3-B4
This energetic session provides the opportunity to meet with editors of Blood Vessels, Thrombosis & Hemostasis, one of ASH’s newer journals. This journal focuses on clinical and mechanistic insights into normal and disordered hemostasis and vascular function, covering acquired bleeding, thrombosis, and conditions affecting veins, arteries, and microvasculature. Whether you're curious about how editorial decisions get made, want to sharpen your peer review skills, or are exploring how to share your research more effectively, these sessions offer real access and insight.
Seating is limited and available on a first-come, first-served basis. This session will be held at the Blood Journals Studio, which is located in the ASH Poster Hall (Orange County Convention Center, West Hall B3-B4).
Speaker:
Keith McCrae
, MD
Cleveland Clinic
Cleveland,
OH, United States
Meet the Journal Editors: Bloo
How I Treat
How I Incorporate Mutational Profiling into Treatment of AML: Considerations Based on Age, Complex Cytogenetics, and Other Clinical Factors
Sunday, December 7, 2025, 8:00 a.m. - 9:00 a.m.
Hyatt - Bayhill 31-32
Speaker:
Jessica Kaplan Altman, MD
Northwestern University
Chicago, IL, United States
How I Incorporate Novel Therapies into Hodgkin Lymphoma Treatment: Frontline vs. Relapse
Sunday, December 7, 2025, 8:00 a.m. - 9:00 a.m.
Hyatt - Bayhill 29-30
Speaker:
Alex Francisco Herrera, MD
City of Hope
Los Angeles, CA, United States
How I Navigate Arterial Thrombosis: A Hematologist's Perspective
Saturday, December 6, 2025, 8:00 a.m. - 9:00 a.m.
Hyatt - Bayhill 23
Speaker:
Jori May, MD
University of Alabama at Birmingham
Birmingham, AL, United States
How I Optimize Hemophilia Management: The Role of Novel Treatments
Sunday, December 7, 2025, 8:00 a.m. - 9:00 a.m.
Hyatt - Bayhill 25-26
Speaker:
Mark Reding, MD
University of Minnesota Medical School
Minneapolis, MN, United States
How I Treat Baby on Board: Managing the Hematological Pregnant Patient
Sunday, December 7, 2025, 8:00 a.m. - 9:00 a.m.
Hyatt - Bayhill 23-24
Speaker:
Sarah O'Brien
Nationwide Children's Hospital
Columbus, OH, United States
How I Treat Clinical Management of Refractory ITP
Sunday, December 7, 2025, 8:00 a.m. - 9:00 a.m.
Hyatt - Bayhill 27
Speaker:
Sandhya Panch, MD
University of Washington
Seattle, WA, United States
How I Treat Isolated CNS Relapse of B-ALL in the Era of Immunotherapy
Saturday, December 6, 2025, 8:00 a.m. - 9:00 a.m.
Hyatt - Bayhill 27
Speaker:
Colleen Annesley, MD
University of Washington
Seattle, WA, United States
How I Treat Multiple Myeloma Progression After Upfront Quadruplet Therapy
Saturday, December 6, 2025, 8:00 a.m. - 9:00 a.m.
Hyatt - Bayhill 31-32
Speaker:
Luciano Jose Costa, MD, PhD
University of Alabama at Birmingham
Birmingham, AL, United States
How I Treat The Balancing Act of Anticoagulant Management in Hemoglobinopathies
Saturday, December 6, 2025, 8:00 a.m. - 9:00 a.m.
Hyatt - Bayhill 25-26
Speaker:
Ted Wun, MD
UC Davis School of Medicine
Sacramento, CA, United States
How I Use NGS in the Pre and Post-HSCT and Cell Therapy Setting
Saturday, December 6, 2025, 8:00 a.m. - 9:00 a.m.
Hyatt - Bayhill 29-30
Speaker:
Michael Pulsipher, MD
University of Utah Health
Salt Lake City, UT, United States
Meet the Scientist
Meet The Scientist: Clonal Evolution in Acute Myeloid Leukemia
Sunday, December 7, 2025, 8:00 a.m. - 9:00 a.m.
Hyatt - Bayhill 19
Speaker:
Ulrich Steidl Jr, MD, PhD
Albert Einstein College of Medicine - Montefiore Einstein
Bronx, NY, United States
Meet The Scientist: Genomics and Targeted Therapy in Pediatric Acute Leukemia
Saturday, December 6, 2025, 8:00 a.m. - 9:00 a.m.
Hyatt - Bayhill 19
Speaker:
Yana Pikman, MD
Dana-Farber Cancer Institute and Boston Children's Hospital
Boston, MA, United States
Meet The Scientist: Hematopoietic Clones - To Be or Not to Be
Sunday, December 7, 2025, 8:00 a.m. - 9:00 a.m.
Hyatt - Bayhill 22
Speaker:
Benjamin Ebert, MD
Dana-Farber Cancer Institute
Boston, MA, United States
Meet the Scientist: Molecularly Targeted Therapies in Lymphoma
Sunday, December 7, 2025, 8:00 a.m. - 9:00 a.m.
Hyatt - Bayhill 17-18
Speaker:
Oliver Weigert, MD
Ludwig-Maximilians-Universität München
Munich, Germany
Meet The Scientist: Myeloma Biology and Therapy
Saturday, December 6, 2025, 8:00 a.m. - 9:00 a.m.
Hyatt - Bayhill 20
Speaker:
Lawrence H Boise, PhD
Emory University
Atlanta, GA, United States
Meet The Scientist: Never Go Into Transplant Waters Alone
Saturday, December 6, 2025, 8:00 a.m. - 9:00 a.m.
Hyatt - Bayhill 22
Speaker:
Sonata Jodele, MD
Cinncinati Children's
Cincinnati, OH, United States
Meet The Scientist: Novel Genetic Markers in Blood Transfusion for Improved Matching
Sunday, December 7, 2025, 8:00 a.m. - 9:00 a.m.
Hyatt - Bayhill 20
Speaker:
Stella T Chou, MD
University of Pennsylavania School of Medicine
Philadelphia, PA, United States
Meet The Scientist: Somatic Genetic Rescue in Bone Marrow Failure Syndromes – Friend or Foe?
Saturday, December 6, 2025, 8:00 a.m. - 9:00 a.m.
Hyatt - Bayhill 17-18
Speaker:
Marcin W Wlodarski, MD, PhD
St. Jude Children's Research Hospital
Memphis, TN, United States
Population Health
Education Program
Our Patient Is Pregnant: Comanaging Obstetric Patients With Complex Hematologic Issues During Their Pregnancy and Delivery
| Sunday, December 7, 2025, 9:30 a.m. - 10:45 a.m. Hyatt - Regency Ballroom S |
Pregnant women comprise a population with exceptionally challenging sets of problems for the consulting hematologist. This session, held in conjunction with the Foundation for Women & Girls with Blood Disorders will focus on three sets of hematologic problems faced by pregnant women. In many cases, there are no evidence-based guidelines for optimal management, but only expert opinion and case series, making management decisions even more challenging.
Dr. Bethany Samuelson Bannow will present the risks and hemostatic changes associated with pregnancy in individuals with and without bleeding disorders. Essential components of delivery planning in patients with bleeding disorders will be discussed, including mode of delivery and neuraxial anesthesia.
Dr. Donald Arnold will review management of immune thrombocytopenia (ITP) in pregnancy, including management of refractory ITP and what is known about use of thrombopoietin receptor agonists in pregnancy.
Dr. Lydia Pecker will present best practices for management of high-risk pregnancies in patients with sickle cell disease and how to proactively strategize to best improve outcomes for both moms and babies.
Chair:
Alice Ma, MD
University of North Carolina at Chapel Hill
Chapel Hill, NC, United States
Speakers:
Bethany Samuelson Bannow, MD,PhD
Oregon Health and Science University
Portland, OR, United States
Pregnancy Management for Patients with Bleeding Disorders
Donald Arnold, MD
McMaster University
Hamilton, ON, Canada
A Practical Approach to Immune Thrombocytopenia in Pregnancy
Lydia Pecker, MD
Johns Hopkins University
Baltimore, MD, United States
Proactive Management to Improve Outcomes in High-Risk Sickle Cell Disease Pregnancy
Update in Hemophilia Across the Lifespan: Novel Therapies/Gene Therapy/Issues in Older Patients
| Monday, December 8, 2025, 10:30 a.m. - 11:45 a.m. OCCC - W307 |
Driven by remarkable scientific achievements over the last half-century, the life expectancy of individuals with severe hemophilia has reached that of the general population. Tailoring therapy to each patient’s deficiency, age, clinical circumstances, and life goals requires treating clinicians to be knowledgeable about therapeutic options to support shared decision-making.
This session provides an update on hemophilia across the lifespan, covering the broad array of current therapies, their mechanism of action, and application in clinical practice.
The first talk provides an overview of gene therapy for hemophilia, which has arrived in the clinic with two approved medications — one for hemophilia A and one for hemophilia B. The basics of gene therapy and their application to clinical practice will be addressed. Dr. Guy Young will "deconstruct" gene therapy by explaining the various components and delivery systems, followed by a brief review of approved products, clinical trial results, and a discussion of novel approaches for hemophilia gene therapy under study. Lastly, gene therapy center logistics and patient selection will be presented.
In the second talk, Dr. Mark Reding will discuss the evolution of the treatment landscape over the last decade, and how the introduction of several therapies with novel mechanisms of action has created new challenges for clinicians to select optimal individual treatment. The development of extended half-life factor products, factor VIII mimetics, and rebalancing therapies will be reviewed. This talk emphasizes the treatment consideration complexity and the need for a nuanced approach to patient/family education to align with the shared decision-making model of care.
In the third talk, Dr Lim will provide a discussion on issues related to aging patients with hemophilia. Medical conditions affecting the general population are observed in aging hemophilia patients; these conditions include, but are not limited to, obesity, diabetes, cardiovascular disease, and malignancy. Monitoring, preventative care, and treatment of these conditions often represent gaps in care for the hemophilia population; primary care providers may be hesitant to provide needed interventions and/or patients may have difficulty identifying a consistent primary care provider. Specific issues related to hemophilia sequela, including liver and bone health, gait instability, and risk for falls and fractures, must be considered. The need for adequate support for aging individuals and the potential development of frailty is amplified when continued underlying bleeding disorder treatment is required with other medical conditions. Through current treatment advances that support decreased risk of hemophilia-associated sequela, and increased general health preventative measures, the hemophilia population may realize improved longevity while maintaining “wellness," while also achieving personal goals and best outcomes.
Chair:
Amy Shapiro, MD
Indiana Hemophilia and Thrombosis Center
Indianapolis, IN, United States
Speakers:
Mark Reding, MD
University of Minnesota Medical School
Minneapolis, MN, United States
New Therapies in Hemophilia: Extend the Half-Life, Bypass, or Rebalance?
Guy Young, MD
Children's Hospital Los Angeles
Los Angeles, CA, United States
Deconstructing Gene Therapy in Hemophilia for the Clinician
Ming Lim, MBBCh, MS
University of Utah
Salt Lake City, UT, United States
The Ageing Hemophilia Patient
Industry Forums
Evolving Patient Support Programs: Access, Education and Affordability in Oncology Care
| Saturday, December 6, 2025, 8:00 a.m. - 9:00 a.m. OCCC - W203AB |
For in-person participants only back to top
Press Program Presentations
More Than Medicine: Improving Patient Experience and Access
| Saturday, December 6, 2025, 7:15 a.m. - 8:15 a.m. OCCC - W221D |
Speaker:
Richard Godby, MD
Mayo Clinic
Rochester, MN, United States
Implementation of a multidisciplinary quality improvement project standardizing an approach to screening and treating iron deficiency in pregnancy
Scientific Program
CARs for Kids: Chimeric Antigen Receptor T-cell Therapy for Childhood Leukemias
| Saturday, December 6, 2025, 2:00 p.m. - 3:15 p.m. OCCC - Tangerine Ballroom F3-4 |
Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment landscape of pediatric leukemias, achieving remission rates in children with otherwise refractory disease. Yet, despite its promise, significant challenges remain in achieving durable remissions, expanding efficacy beyond B-cell malignancies, and safely applying this approach across diverse leukemia subtypes. This session will explore the latest translational and clinical advances driving the next generation of CAR-T therapies for childhood leukemias. Together, the talks featured in this session will provide a forward-looking view of how cutting-edge CAR-T innovations are reshaping pediatric leukemia treatment—from B-acute lymphoblastic leukemia (ALL) to acute myeloid leukemia (AML)—and paving the way toward broader, more durable cures.
Dr. Sara Ghorashian will review clinical outcomes in relapsed and refractory B-cell ALL and discuss novel strategies to enhance CAR-T efficacy, mitigate relapse, and evaluate the potential for introducing CAR-T earlier in therapy.
Dr. Maksim Mamonkin will address the unique challenges of developing CAR-T therapy for T-cell ALL. His presentation will highlight innovative antigen-targeting approaches, and engineering strategies to overcome T-cell self-death and aplasia, and the most recent results from emerging clinical trials that signal progress in this difficult leukemia subtype.
Dr. Paulina Velasquez will focus on solutions to two critical barriers in AML: antigen heterogeneity and the immunosuppressive tumor microenvironment. She will discuss dual-targeted CAR constructs and preclinical immunocompetent models designed to optimize therapeutic efficacy.
Chair:
Julie Jaffray, MD
Rady Children's Hospital, University of California, San Diego
San Diego, CA, United States
Speakers:
Sara Ghorashian, FRCPath, PhD
Great Ormond Street Institute of Child Health
London, ENG, United Kingdom
CAR T-Cell Breakthroughs: Shaping the Future of B-Cell ALL Treatment
Maksim Mamonkin, PhD
Baylor College of Medicine
Houston, TX, United States
T-Cell ALL Meets CAR-T: Advancements and Breakthroughs
Paulina Velasquez, MD
St. Jude Children's Hospital
Memphis, TN, United States
Harnessing CAR-T: A New Era in AML Treatment
Scientific Spotlight Sessions
Bridging Translational Science and Clinical Trials to Transform Burkitt Lymphoma Research Globally
| Monday, December 8, 2025, 10:30 a.m. - 11:45 a.m. OCCC - Tangerine Ballroom F2 |
The treatment of Burkitt’s lymphoma (BL) is a testament to the profound curative potential of combination chemotherapy, and most patients are cured with modern treatment approaches that utilize intensive chemotherapy along with aggressive supportive care. Still, gaps remain for patients unable to tolerate intensive chemotherapy, for those with disease that become resistant to chemotherapy, and for those who live in areas of the world with fewer supportive care resources. This session will examine the current understanding of the molecular biology of BL, the tumor microenvironment and how this might influence clinical and translational research efforts. It will also explore and highlight significant efforts in Sub-Saharan Africa that attempt to bridge the gap and improve outcomes globally.
Dr. Mark Roschewski will describe the history of BL and its emergence as one of the most sensitive subtypes of lymphoma to chemotherapy. More recently, the field has come to understand molecular subtypes of BL that may have differential response to immunotherapy and/or targeted agents. Dr. Roschewski will also address the role of the tumor microenvironment and its relevance in clinical outcomes.
Dr. Clara Chamba will present progress from the Aggressive Infection-Related East African Lymphoma (AI-REAL) study, focusing on innovative approaches to diagnosing and managing BL in Sub-Saharan Africa. She will highlight minimally invasive diagnostic strategies, share key insights from recent validation efforts, and discuss lessons learned in building sustainable capacity for lymphoma care in resource-limited settings. Dr. Chamba will also reflect on the collaborative model that brought together international partners and local institutions to address diagnostic delays. Finally, she will outline the broader implications of this work for advancing equitable access to timely cancer diagnosis across low- and middle-income countries.
Speakers:
Mark Roschewski, MD
NIH/NIC
Bethesda, MD, United States
Translating Knowledge about Burkitt Lymphoma Genomics and Microenvironment into Novel Clinical Trials
Clara Chamba
Muhimbili University of Health and Allied Sciences
Dar-es-Salaam, Tanzania
Burkitt Lymphoma Research in Africa: Overcoming Challenges and Unlocking Translational Potential
Scientific Workshops
Disease Severity Scoring in Sickle Cell Disease
| Friday, December 5, 2025, 3:05 p.m. - 3:45 p.m. OCCC - W315 |
Speakers:
Jane Hankins, MD,MS
St Jude Children's Research Hospital
Memphis, TN, United States
Moderator Introduction: Topic Only
Elizabeth Klings
Boston University
Boston, MA, United States
Prior Disease Severity Scoring Systems
Courtney Thornburg
Rady Children's Health - Orange County
Orange, CA, United States
Defining Disease Severity for NHLBI Innovative Trials
Tarun Aurora, MD, MSCI
Emory University
Atlanta, GA, United States
A New Severity Classification System (SCOGS)
Special-Interest Sessions
ASH Clinical Practice Guidelines on Diagnosis of Iron Deficiency with and without Anemia
| Saturday, December 6, 2025, 4:00 p.m. - 5:30 p.m. Hyatt - Regency Ballroom OPQ |
In this session, speakers will highlight recommendations from the upcoming ASH guidelines on diagnosis of iron deficiency and will discuss important considerations for the application of the recommendations in practice.
Chair:
Jacquelyn Powers, MD
Texas Children's Hematology Center
Houston, TX, United States
Speakers:
Imo Akpan, MD
Columbia University Irving Medical Center
New York, NY, United States
Ferritin, TSAT, and how low is too low: Diagnosis of iron deficiency in adults
Layla Van Doren, MD,MBA
Yale School of Medicine
New Haven, CT, United States
Menstruating individuals: Evidence-based ferritin thresholds
Michelle Sholzberg, MD
University of Toronto
Toronto, ON, Canada
Screening and defining iron deficiency in pregnant individuals
ASH Clinicians in Practice Lunch: Access to Critical Drugs: The Causes, Costs, and Campaigns
| Sunday, December 7, 2025, 11:15 a.m. - 12:30 p.m. Hyatt - Florida Ballroom |
Chair:
Mary-Elizabeth Percival, MD
Seattle Cancer Care Alliance
Seattle, WA, United States
Speakers:
Thomas Roades
Duke-Margolis Institute for Health Policy
Durham, NC, United States
The interactions of the pharmaceutical system and how the competing demands of different stakeholders can influence cost and shortages
Emily Mackler
YesRX
Ann Arbor, MI, United States
Combatting drug shortages with drug repository programs
Brooke Boring
Hematology/Oncology Pharmacy Association
Milwaukee, WI, United States
Advocacy at the federal and state level and how practitioners can get engaged
Celebrating Diverse Voices: Enriching Hematology Lunch
| Monday, December 8, 2025, 12:00 p.m. - 1:30 p.m. Hyatt - Florida Ballroom A |
This is a community-building and networking event for members from an expansive and inclusive group of communities attending the meeting. The event is hosted by the Committee on Advancing Excellence and Population Health and aims to create space for these communities to learn more about the differing experiences and needs across communities and create a sense of belonging and allyship. This year’s event will include inspiring remarks from a fellow member and networking opportunities throughout. back to top
How Can Community-Based and Academic Hematologists Foster Clinical Trial Participation as Part of Patient Care?
| Sunday, December 7, 2025, 9:30 a.m. - 11:00 a.m. Hyatt - Plaza Int'l HIJK |
Patients often learn about clinical trials from their healthcare providers. However, the barriers to trial participation include: patients not being offered trials; physicians not having the capacity to effectively navigate clinicaltrials.gov and enroll patients; and community-based physicians are often not engaged (or engaged early enough to make a meaningful impact) in the clinical trial life cycle. This session will (1) address barriers that practicing hematologists face offering trials to patients, (2) provide practical solutions to overcome these barriers and (3) highlight best practices to engage patients and increase participation in trials.
Speakers will consist of a mix of practicing hematologists as well as other stakeholders in the clinical trial enterprise sharing their perspectives on the issue. The session will conclude with the speakers providing practical tactics that the audience can take to enhance access, inclusivity, and ultimately representation in hematology trials.
Chair:
Leonard Valentino
Rush University Medical Center
New York, NY, United States
Speakers:
Leonard Valentino
Rush University Medical Center
New York, NY, United States
Challenges to Clinical Trial Participation
Lanre Tunji-Ajayi, MS
Sickle Cell Awareness Group of Ontario
Pickering, ON, Canada
Patient Perspective
John M. M. Burke, MD
Rocky Mountain Cancer Centers
Aurora, CO, United States
Engagement of Community Physicians in Clinical Trials
Fabio Dennstaedt
University Hospital and University of Bern
Bern, Switzerland
Moving Patients to Participants in Hematology Clinical Trials
Stephanie Valer Seremetis, MD
Novo Nordisk A/S
Plainsboro, NJ, United States
Industry Perspective
Alysha Croker
Health Canada
Ottawa, ON, Canada
Government Perspective
Jeffrey Keefer, MD,PhD
IQVIA
Keswick, VA, United States
Contract Research Organization Perspective
Michelle Feige
Accreditation of Human Research Protection Programs (AAHRPP)
Washington, DC, United States
Institutional Review Board Perspective
Leveraging Genetic Diversity in Preclinical Discovery to Guide Precision Medicine
| Saturday, December 6, 2025, 9:30 a.m. - 10:45 a.m. OCCC - W314 |
Consideration for variability in the
constitutional DNA in medical research presents a unique opportunity to uncover
novel biology, identify population-specific risk factors, and develop tailored
therapies. By embracing the genetic and environmental variations across
populations, we can unlock new avenues for innovation. While the clinical
impact of variations in the somatic genetic profile, clinical presentation and
survival prognostications are recognized, there is an unmet need to better
understand the underlying biology of sometimes contrasting genotype-phenotype
associations originating from varying germline genetic ancestries. This is
caused by difficulties of biologically faithful functionalization approaches,
and also limitations in the availability of suitable model organisms.
This session will present examples of bench-to-bedside translations, new model systems and basic research tools that have broad applicability for both basic and translational researchers. It may catalyze collaborations between translational researchers and basic scientists. In addition, the session aims to bridge the gap between clinical practice and basic research by exploring the critical role of genetic variation as a proxy for advancing precision medicine.
Attendees of the session will leave with an appreciation for the importance of considering genetic variation in research and cross-disciplinary partnerships to drive meaningful advances in patient treatment and survival.
Speakers:
Kellie Machlus, PhD
Boston Children's Hospital
Boston, United States
Discovery Based on Population Structure: How to Faithfully Understand and Functionalize Novel Treatments
Adam J de Smith
University of Southern California Keck School of Medicine
Los Angeles, CA, United States
Decoding Bias in Disease Risk: The Role of Ancestry and Genomic Variant Clustering
Jesse Boehm Jr
MIT
Cambridge, MA, United States
Moving Towards Precision Medicine: Influence of Germline and Ancestry on Preclinical Target Discovery
LGBTQIA+ Community Networking Brunch
| Sunday, December 7, 2025, 11:00 a.m. - 12:30 p.m. Hyatt - Plaza Int'l DEFG |
This is a community-building and networking event for members of the LGBTQIA+ community attending the meeting. The event is hosted by the Committee on Advancing Excellence and Population Health and aims to create a sense of belonging and allyship. This year’s event will include breakout group discussion on mentorship, community building, and career advancement followed by speed networking. back to top
Medical Educators' Symposium
| Sunday, December 7, 2025, 7:00 a.m. - 9:00 a.m. Hyatt - Plaza Int'l DEFG |
The ASH 2025 Medical Educators Symposium will be focused on cultural evolutions, both for academic medical practice and trainee education. Medical education and patient care are rapidly transforming from the perspective of inclusivity, cultural humility, and mixed methods of teaching. Come hear from educational experts about how to better engage trainees through revolutionary multimedia approaches as well. Regardless of your training level or faculty rank, come join the conversation and share your perspectives. Everyone's voice matters!
Chair:
Alexander Boucher, MD
University of Minnesota
Minneapolis, MN, United States
Speakers:
Robert Stern, MD
Dana-Farber Cancer Institute
Boston, MA, United States
General Session 1: The Evolving Landscape of Cultural Terminology in Hematology Part 1
Laura DeCastro, MD
University of Pittsburgh Medical Center
Pittsburgh, PA, United States
General Session 1: The Evolving Landscape of Cultural Terminology in Hematology Part 2
Jean M. Connors, MD
Harvard Medical School
Boston, MA, United States
General Session 2: Tips and Tricks to Efficiently Handle Knowledge Gathering Part 1
Jori May, MD
University of Alabama at Birmingham
Birmingham, AL, United States
General Session 2: Tips and Tricks to Efficiently Handle Knowledge Gathering Part 2
Ronak Mistry, DO
University of Pennsylvania
Philadelphia, PA, United States
General Session 3: Content Creation as Medical Educators Part 1
Jonaphine Mata, MD
Johns Hopkins University
Baltimore, MD, United States
General Session 3: Content Creation as Medical Educators Part 2
Alexander Boucher, MD
University of Minnesota
Plymouth, MN, United States
General Session Q&A
Marina Heskel, MD
University of California San Francisco
San Francisco, CA, United States
Breakout 2: Mixed Methods Educational Strategies for All Learners - Facilitator A
Reed E. Drews, MD
Beth Israel Deaconess Medical Center
Boston, MA, United States
Breakout 2: Mixed Methods Educational Strategies for All Learners - Facilitator B
Rohini Jain, MD
University of California San Francisco
San Francisco, CA, United States
Breakout 3: Cultural Humility in Hematology Care - Facilitator B
Sana Saif Ur Rehman, MD
Washington University in St Louis
Saint Louis, MO, United States
Breakout 4: Innovation in Education for the Current Generation - Facilitator A
Thomas Deloughery, MD
Oregon Health and Science Univ.
Portland, OR, United States
Breakout 4: Innovation in Education for the Current Generation - Facilitator B
Treating Fairly Rounds Lunch
| Sunday, December 7, 2025, 11:30 a.m. - 12:30 p.m. Hyatt - Manatee Spring |
The Treating Fairly Rounds Lunch session will
- Introduce the role of language (and cultural diversity) in the delivery of health care for non-English speaking populations
- Discuss the impact of language barrier on the utilization of old and novel therapies, patient compliance, safety, and disease outcomes
- Present potential solutions to overcome some of the challenges posed by language barriers and improve healthcare quality and patient outcomes.
Speakers:
Rahma Warsame, MD
Mayo Clinic
Rochester, MN, United States
Healthcare Access to Non-English Speaking Populations - Presenter 1
Cesar Rodriguez Valdes, MD
Icahn School of Medicine at Mount Sinai
New York, NY, United States
Healthcare Access to Non-English Speaking Populations - Presenter 2
Updated ASH Clinical Practice Guidelines on Acute Myeloid Leukemia (AML) in Older Adults
| Sunday, December 7, 2025, 9:30 a.m. - 11:00 a.m. OCCC - W414CD |
In this session, speakers will highlight recommendations from the updated ASH guidelines on AML in older adults and will discuss important considerations for the application of the recommendations in practice.
Chair:
Mikkael Sekeres, MD
Sylvester Comprehensive Cancer Center, University of Miami
Miami, FL, United States
Speakers:
Kah Poh (Melissa) Loh, MD, MS
University of Rochester Medical Center
Rochester, NY, United States
Treatment Options for Older Adults with AML: Recommendations on Low-Dose Cytarabine, Azacitidine, and Decitabine Regimens as Monotherapy or Combinations
Luca Malcovati, MD
University of Pavia and IRCCS S. Matteo Hospital Foundation
Pavia, PV, Italy
Treatment Options for Older Adults with AML and IDH1/IDH2 Mutations: Recommendations on HMA Monotherapy, Combinations with Venetoclax, and Targeted Therapies
Maria R. Baer, MD
University of Maryland
Baltimore, MD, United States
Recommendations for Treatment for Older Adults with AML and FLT3 Mutations
Trainee Activities and Services
Career Development Lunch
| Saturday, December 6, 2025, 11:15 a.m. - 12:15 p.m. Hyatt - Windemere Ballroom |
This session provides an intimate venue for trainees to meet with leaders in hematology to discuss careers in the wide array of practice areas within hematology, including basic, clinical, and translational research, PhD careers, careers in industry settings, and careers in private and clinical practice. There will are multiple tables dedicated to each career area and one faculty member at each table leading the discussion. A boxed lunch is provided. This is a first come, first served event that is usually very-well attended. The full list of topics covered are: Adult BMT/Cellular Therapy; Pediatric BMT/CAR-T; Adult Clinical Malignant Hematology; Adult Clinical Classical Hematology; Pediatric Clinical Classical Hematology; Pediatric Hematology/Oncology; Private Practice Hematology; Government Careers; Industry Careers; Laboratory and Translational Hematology; Medical Educators in Hematology; PhD Careers; International Opportunities Hematology; Women's Health; Medical Informatics and AI; Lifespan Hematology; Geriatric Hematology; International Graduate Hematology; Administrative Careers in Hematology; and Hematology-Focused Fellowship Training Program.
Chair:
Leidy Isenalumhe, MD, MS
Moffitt Cancer Center
Lutz, FL, United States
Speakers:
Rawan Faramand, MD
Moffitt
Tampa, FL, United States
Adult BMT/Cellular Therapy
Lori Muffly, MD
Stanford University
Stanford, CA, United States
Adult BMT/Cellular Therapy
Gunjan L. Shah, MD, MS
Memorial Sloan Kettering
New York, NY, United States
Adult BMT/Cellular Therapy
Azra Borogovac
City of Hope
Irvine, CA, United States
Adult BMT/Cellular Therapy
Neel Bhatt, MBBS,MPH
Fred Hutch
Seattle, WA, United States
Pediatric BMT/CAR-T
Kris Mahadeo
Duke University
Houston, TX, United States
Pediatric BMT/CAR-T
Dorothea Douglas, MD
Nemours
Orlando, FL, United States
Pediatric BMT/CAR-T
Ajay Major, MD, MBA
University of Colorado Cancer Center
Denver, CO, United States
Adult Clinical Malignant Hematology
Hira Shaikh, MD
University of Iowa Caver College of Medicine
Iowa City, IA, United States
Adult Clinical Malignant Hematology
Jennifer L. Crombie, MD
Dana Farber Cancer Institute
Boston, MA, United States
Adult Clinical Malignant Hematology
Gabriela Soriano Hobbs, MD
Massachusetts General Hospital
Boston, MA, United States
Adult Clinical Malignant Hematology
Ronak Mistry, DO
University of Pennsylvania
Philadelphia, PA, United States
Adult Clinical Classical Hematology
Alice Ma, MD
University of North Carolina at Chapel Hill
Chapel Hill, NC, United States
Adult Clinical Classical Hematology
Peter Kouides, MD
University of Rochester
Rochester, NY, United States
Adult Clinical Classical Hematology
Thomas Coates, MD
Children's Hospital of Los Angeles
Los Angeles, CA, United States
Pediatric Clinical Classical Hematology
Neha Bhasin, MD
Beinoff Children's
Oakland, CA, United States
Pediatric Clinical Classical Hematology
Melissa Rose, DO
Nationwide Children’s Hospital
Columbus, OH, United States
Pediatric Clinical Classical Hematology
Deepa Bhojwani, MD
Children's Hospital of Los Angeles
Los Angeles, CA, United States
Pediatric Hematology/Oncology
Rayne Rouce, MD
Texas Children's Hospital
Houston, TX, United States
Pediatric Hematology/Oncology
Venee N. Tubman, MD MMSc
Texas Children's Cancer and Hematology Centers
Houston, TX, United States
Pediatric Hematology/Oncology
Camila Masias, MD,MPH
Miami Cancer Institute
Miami, FL, United States
Community Practice Hematology
Matthew Ulrickson, MD
MD Anderson Medical Center/Banner Health
Gilbert, AZ, United States
Community Practice Hematology
Donna DiMichele, MD
NIH
Washington, DC, United States
Government Careers
Relja Popovic, PhD
AbbVie
North Chicago, IL, United States
Industry Careers
Weili Sun
Janssen Pharmaceutical
Los Angeles, CA, United States
Industry Careers
Nina Shah, MD
AstraZeneca
South San Francisco, CA, United States
Industry Careers
Olga Guryanova
University of Florida
Gainesville, FL, United States
Laboratory and Translational Hematology
Bob Lowenberg, MD,PhD
Erasmus University Medical Center
Rotterdam, Netherlands
Laboratory and Translational Hematology
Sherine F Elsawa, PhD
University of New Hampshire
Durham, NH, United States
Laboratory and Translational Hematology
Lori Rosenstein, MD
Gunderson Health
La Crosse, WI, United States
Medical Education in Hematology
Catherine E McGuinn, MD
Cornell University
New York, NY, United States
Medical Education in Hematology
Leslie Ellis, MD
Wake Forest University School of Medicine
Winston Salem, NC, United States
Medical Education in Hematology
Anna Beaudin, PhD
University of Utah
Salt Lake City, UT, United States
PhD Careers
Ze Zheng
Versiti Blood Research Institute
Milwaukee, WI, United States
PhD Careers
Andres Gomez-De Leon Jr, MD
Universidad Autonoma de Nuevo Leon
Monterrey, Mexico
International Opportunities in Hematology
Eugenia Asare, MD, MBChB
Ghana Institute of Clinical Genetics
Accra, Ghana
International Opportunities in Hematology
Bethany Samuelson Bannow, MD,PhD
Oregon Health and Science University
Portland, OR, United States
Women's Health
Alecia Nero, MD
UT Southwestern Medical Center
Dallas, TX, United States
Women's Health
Becky Zon, MD
Brigham and Women's Hospital
West Roxbury, MA, United States
Women's Health
Swami P. Iyer, MD
MD Anderson Cancer Center
Houston, TX, United States
Medical Informatics and AI
Neil Zakai
University of Vermont
Burlington, VT, United States
Medical Informatics and AI
William Wood, MD, MPH
University of North Carolina At Chapel Hill Hospital
Chapel Hill, NC, United States
Medical Informatics and AI
Leidy Isenalumhe, MD, MS
Moffitt Cancer Center
Lutz, FL, United States
Lifespan Hematology
Dan Hart
Roche
Welwyn Garden City, England, United Kingdom
Lifespan Hematology
Julie Kanter, MD
University of Alabama at Birmingham
Birmingham, AL, United States
Lifespan Hematology
Maya Abdallah, MD
Boston University
Boston, MA, United States
Geriatric Hematology
Hira Mian, MD
McMaster University
Hamilton, ON, Canada
Geriatric Hematology
Tanya Wildes, MD,MSc
University of Nebraska
Omaha, NE, United States
Geriatric Hematology
Tania Jain, MBBS
Johns Hopkins University
Baltimore, MD, United States
International Graduate Hematology
Saad Z. Usmani, MD
Memorial Sloan Kettering Cancer Center
New York, NY, United States
International Graduate Hematology
Jessica Maria Stempel, MD, MHS
Yale School of Medicine
New Haven, CT, United States
International Graduate Hematology
Ana Antun, MD
Emory University
Decatur, GA, United States
Hematology-Focused Fellowship Training Program
Reed E. Drews, MD
Beth Israel Deaconess Medical Center
Boston, MA, United States
Hematology-Focused Fellowship Training Program
Amy Zhou, MD
Washington University School of Medicine
Saint Louis, MO, United States
Hematology-Focused Fellowship Training Program
Yvonne Efebera, MD, MPH
Ohio Health
Columbus, OH, United States
Administrative Careers in Hematology
John Byrd, MD
University of Cincinnati
Cincinnati, OH, United States
Administrative Careers in Hematology
Usha S Perepu
UT Health San Antonio
San Antonio, TX, United States
Administrative Careers in Hematology
Trainee Didactic Session: Outcomes Research in Hematology
| Monday, December 8, 2025, 12:15 p.m. - 1:15 p.m. OCCC - W308 |
In this educational session, speakers will discuss their approach to outcomes research by walking through specific examples and successful strategies to tackle large data. Speakers will discuss the where/when/how/why of comparative effectiveness research, including systematic reviews, and how it can inform future studies and current clinical practice. In addition, they will explain the advantages and disadvantages of population-based research, and how to go about making your own database.
Chair:
Reshma Ramlal
Moffitt Cancer Center
Tampa, FL, United States
Adam S Kittai, MD
Icahn School of Medicine at Mount Sinai
New York, NY, United States
Speakers:
Scott Huntington, MD, MPH
Yale School of Medicine
New Haven, CT, United States
Outcomes Research in Hematology
Mengyang Di, MD, PhD
Fred Hutchinson Cancer Center
Seattle, WA, United States
Outcomes Research in Hematology
Treating Fairly Talks
A Holistic Approach: The Sickle Cell Foundation of Georgia, Inc. & The Sickle Cell Sanctuary
| Monday, December 8, 2025, 8:30 a.m. - 9:00 a.m. OCCC - Hall C ASH Studio |
As part of our commitment to excellence through expansion and inclusion, the American Society of Hematology (ASH) is offering the ASH Treating Fairly Talks. This inclusive space is designed to help attendees recognize the drivers of differing outcomes for various populations as viewed through the hematology lens and provide tools to make changes in their institutions. These sessions will include a short expert commentary followed by facilitated conversations about actions that can be taken to drive change at your institution. The Treating Fairly Talks will take place at the ASH Studio, located in ASH Central (Orange County Convention Center, West Hall C).
Ms. Tabatha McGee, CEO of the Sickle Cell Foundation of Georgia, Inc., will present on successful community-centric initiatives for sickle cell disease.Speaker:
back to topA Holistic Approach: The Sickle Cell Foundation of Georgia, Inc. & The Sickle Cell Sanctuary
| Sunday, December 7, 2025, 1:30 p.m. - 2:00 p.m. OCCC - Hall C ASH Studio |
As part of our commitment to excellence through expansion and inclusion, the American Society of Hematology (ASH) is offering the ASH Treating Fairly Talks. This inclusive space is designed to help attendees recognize the drivers of differing outcomes for various populations as viewed through the hematology lens and provide tools to make changes in their institutions. These sessions will include a short expert commentary followed by facilitated conversations about actions that can be taken to drive change at your institution. The Treating Fairly Talks will take place at the ASH Studio, located in ASH Central (Orange County Convention Center, West Hall C).
Ms. Tabatha McGee, CEO of the Sickle Cell Foundation of Georgia, Inc., will present on successful community-centric initiatives for sickle cell disease.Speaker:
Tabatha McGee
Sickle Cell Sanctuary
Atlanta, GA, United States
A Holistic Approach: The Sickl
Breaking Barriers in Blood Cancer: Transforming Access and Outcomes Across Populations
| Sunday, December 7, 2025, 11:00 a.m. - 11:30 a.m. OCCC - Hall C ASH Studio |
As part of our commitment to excellence through expansion and inclusion, the American Society of Hematology (ASH) is offering the ASH Treating Fairly Talks. This inclusive space is designed to help attendees recognize the drivers of differing outcomes for various populations as viewed through the hematology lens and provide tools to make changes in their institutions. These sessions will include a short expert commentary followed by facilitated conversations about actions that can be taken to drive change at your institution. The Treating Fairly Talks will take place at the ASH Studio, located in ASH Central (Orange County Convention Center, West Hall C).
Dr. Tina Bhatnagar will present on the impact of geography on care.Speaker:
back to topBreaking Barriers in Blood Cancer: Transforming Access and Outcomes Across Populations
| Monday, December 8, 2025, 12:00 p.m. - 12:30 p.m. OCCC - Hall C ASH Studio |
As part of our commitment to excellence through expansion and inclusion, the American Society of Hematology (ASH) is offering the ASH Treating Fairly Talks. This inclusive space is designed to help attendees recognize the drivers of differing outcomes for various populations as viewed through the hematology lens and provide tools to make changes in their institutions. These sessions will include a short expert commentary followed by facilitated conversations about actions that can be taken to drive change at your institution. The Treating Fairly Talks will take place at the ASH Studio, located in ASH Central (Orange County Convention Center, West Hall C).
Dr. Tina Bhatnagar will present on the impact of geography on care.Speaker:
Bhavana Bhatnagar, DO
West Virginia University Cancer Institute, Wheeling Hospital
Wheeling, WV, United States
Breaking Barriers in Blood Cancer: Transforming Access and Outcomes Across Populations
Breaking Financial Barriers to Care Through Affordable Innovation
| Saturday, December 6, 2025, 3:30 p.m. - 4:00 p.m. OCCC - Hall C ASH Studio |
As part of our commitment to excellence through expansion and inclusion, the American Society of Hematology (ASH) is offering the ASH Treating Fairly Talks. These sessions will take place at the ASH Studio, located in ASH Central (Orange County Convention Center, West Hall C). This inclusive space is designed to help attendees recognize the drivers of differing outcomes for various populations as viewed through the hematology lens and provide tools to make changes in their institutions. These sessions will include a short expert commentary followed by facilitated conversations about actions that can be taken to drive change at your institution.
Dr. Andres Gomez-De Leon will present on the financial factors to accessing care.
Speaker:
back to topBreaking Financial Barriers to Care Through Affordable Innovation
| Monday, December 8, 2025, 1:00 p.m. - 1:30 p.m. OCCC - Hall C ASH Studio |
As part of our commitment to excellence through expansion and inclusion, the American Society of Hematology (ASH) is offering the ASH Treating Fairly Talks. This inclusive space is designed to help attendees recognize the drivers of differing outcomes for various populations as viewed through the hematology lens and provide tools to make changes in their institutions. These sessions will include a short expert commentary followed by facilitated conversations about actions that can be taken to drive change at your institution. The Treating Fairly Talks will take place at the ASH Studio, located in ASH Central (Orange County Convention Center, West Hall C).
Dr. Andres Gomez-De Leon will present on the financial factors to accessing care.
Speaker:
Andres Gomez-De Leon Jr, MD
Universidad Autonoma de Nuevo Leon
Monterrey, Mexico
Breaking Financial Barriers to Care Through Affordable Innovation
From Precision Medicine to Personalized Care: Meeting Patients Where They Are
| Saturday, December 6, 2025, 1:30 p.m. - 2:00 p.m. OCCC - Hall C ASH Studio |
As part of our commitment to excellence through expansion and inclusion, the American Society of Hematology (ASH) is offering the ASH Treating Fairly Talks. This inclusive space is designed to help attendees recognize the drivers of differing outcomes for various populations as viewed through the hematology lens and provide tools to make changes in their institutions. These sessions will include a short expert commentary followed by facilitated conversations about actions that can be taken to drive change at your institution. The Treating Fairly Talks will take place at the ASH Studio, located in ASH Central (Orange County Convention Center, West Hall C).
Dr. Eneida Nemecek will present on tailoring care for optimal patient outcomes.
Speaker:
back to topFrom Precision Medicine to Personalized Care: Meeting Patients Where They Are
| Sunday, December 7, 2025, 9:00 a.m. - 9:30 a.m. OCCC - Hall C ASH Studio |
As part of our commitment to excellence through expansion and inclusion, the American Society of Hematology (ASH) is offering the ASH Treating Fairly Talks. This inclusive space is designed to help attendees recognize the drivers of differing outcomes for various populations as viewed through the hematology lens and provide tools to make changes in their institutions. These sessions will include a short expert commentary followed by facilitated conversations about actions that can be taken to drive change at your institution. The Treating Fairly Talks will take place at the ASH Studio, located in ASH Central (Orange County Convention Center, West Hall C).
Dr. Eneida Nemecek will present on tailoring care for optimal patient outcomes.
Speaker:
Eneida Nemecek, MD
OHSU Knight Cancer Institute
Portland, OR, United States
From Precision Medicine to Personalized Care: Meeting Patients Where They Are
Impact of Geography on Care
| Saturday, December 6, 2025, 11:00 a.m. - 11:30 a.m. OCCC - Hall C ASH Studio |
As part of our commitment to excellence through expansion and inclusion, the American Society of Hematology (ASH) is offering the ASH Treating Fairly Talks. This inclusive space is designed to help attendees recognize the drivers of differing outcomes for various populations as viewed through the hematology lens and provide tools to make changes in their institutions. These sessions will include a short expert commentary followed by facilitated conversations about actions that can be taken to drive change at your institution. The Treating Fairly Talks will take place at the ASH Studio, located in ASH Central (Orange County Convention Center, West Hall C).
Dr. Norma Ada will present on the impact of geography on care.
Speaker:
back to topImpact of Geography on Care
| Monday, December 8, 2025, 10:00 a.m. - 10:30 a.m. OCCC - Hall C ASH Studio |
As part of our commitment to excellence through expansion and inclusion, the American Society of Hematology (ASH) is offering the ASH Treating Fairly Talks. This inclusive space is designed to help attendees recognize the drivers of differing outcomes for various populations as viewed through the hematology lens and provide tools to make changes in their institutions. These sessions will include a short expert commentary followed by facilitated conversations about actions that can be taken to drive change at your institution. The Treating Fairly Talks will take place at the ASH Studio, located in ASH Central (Orange County Convention Center, West Hall C).
Dr. Norma Ada will present on the impact of geography on care.
Speaker:
Norma Ada
Medical Associates of the Pacific, LLC
Saipan, Northern Mariana Islands
Impact of Geography on Care
Promoting Language Equity in Care and Research
| Saturday, December 6, 2025, 9:00 a.m. - 9:30 a.m. OCCC - Hall C ASH Studio |
As part of our commitment to excellence through expansion and inclusion, the American Society of Hematology (ASH) is offering the ASH Treating Fairly Talks. This inclusive space is designed to help attendees recognize the drivers of differing outcomes for various populations as viewed through the hematology lens and provide tools to make changes in their institutions. These sessions will include a short expert commentary followed by facilitated conversations about actions that can be taken to drive change at your institution. The Treating Fairly Talks will take place at the ASH Studio, located in ASH Central (Orange County Convention Center, West Hall C).
Dr. Alisa Khan will present on the importance of language on outcomes of care.
Speaker:
back to topPromoting Language Equity in Care and Research
| Sunday, December 7, 2025, 4:00 p.m. - 4:30 p.m. OCCC - Hall C ASH Studio |
As part of our commitment to excellence through expansion and inclusion, the American Society of Hematology (ASH) is offering the ASH Treating Fairly Talks. This inclusive space is designed to help attendees recognize the drivers of differing outcomes for various populations as viewed through the hematology lens and provide tools to make changes in their institutions. These sessions will include a short expert commentary followed by facilitated conversations about actions that can be taken to drive change at your institution. The Treating Fairly Talks will take place at the ASH Studio, located in ASH Central (Orange County Convention Center, West Hall C).
Dr. Alisa Khan will present on the importance of language on outcomes of care.
Speaker:
Alisa Khan
Boston Children's Hospital Boston
Boston, MA, United States
Promoting Language Equity in Care and Research
Scientific Spotlight
Bridging Translational Science and Clinical Trials to Transform Burkitt Lymphoma Research Globally
Monday, December 8, 2025, 10:30 a.m. - 11:45 a.m.
OCCC - Tangerine Ballroom F2
The treatment of Burkitt’s lymphoma (BL) is a testament to the profound curative potential of combination chemotherapy, and most patients are cured with modern treatment approaches that utilize intensive chemotherapy along with aggressive supportive care. Still, gaps remain for patients unable to tolerate intensive chemotherapy, for those with disease that become resistant to chemotherapy, and for those who live in areas of the world with fewer supportive care resources. This session will examine the current understanding of the molecular biology of BL, the tumor microenvironment and how this might influence clinical and translational research efforts. It will also explore and highlight significant efforts in Sub-Saharan Africa that attempt to bridge the gap and improve outcomes globally.
Dr. Mark Roschewski will describe the history of BL and its emergence as one of the most sensitive subtypes of lymphoma to chemotherapy. More recently, the field has come to understand molecular subtypes of BL that may have differential response to immunotherapy and/or targeted agents. Dr. Roschewski will also address the role of the tumor microenvironment and its relevance in clinical outcomes.
Dr. Clara Chamba will present progress from the Aggressive Infection-Related East African Lymphoma (AI-REAL) study, focusing on innovative approaches to diagnosing and managing BL in Sub-Saharan Africa. She will highlight minimally invasive diagnostic strategies, share key insights from recent validation efforts, and discuss lessons learned in building sustainable capacity for lymphoma care in resource-limited settings. Dr. Chamba will also reflect on the collaborative model that brought together international partners and local institutions to address diagnostic delays. Finally, she will outline the broader implications of this work for advancing equitable access to timely cancer diagnosis across low- and middle-income countries.
Speakers:
Mark Roschewski, MD
NIH/NIC
Bethesda, MD, United States
Translating Knowledge about Burkitt Lymphoma Genomics and Microenvironment into Novel Clinical Trials
Clara Chamba
Muhimbili University of Health and Allied Sciences
Dar-es-Salaam, Tanzania
Burkitt Lymphoma Research in Africa: Overcoming Challenges and Unlocking Translational Potential
Creative and Novel Statistical Techniques to Design and Analyze Data for Trials Focused on Rare Hematologic Diseases
Monday, December 8, 2025, 10:30 a.m. - 11:45 a.m.
Hyatt - Regency Ballroom R
This session will highlight novel statistical methods and unique design and analysis considerations for clinical trials focused on rare hematologic diseases. It will provide a unique platform for interactive discussion and knowledge sharing on statistical design/analysis of clinical studies, for the clinical community.
Chair:
Fangxin Hong
Pfizer Inc
Cambridge, MA, United States
Speakers:
Arzu Onar-Thomas
St Jude's Children Hospital
Memphis, TN, United States
Rational Compromises in Trial Design for Rare Diseases - Lessons from Pediatric Cancer
Ernest Amankwah
Johns Hopkins All Children's Hospital
St Petersburg, United States
Design and Application of RCT for Rare/Low-Frequency Diseases: From Traditional Parallel-Cohort to Novel Contemporaneous Control Recapture
Epigenomic Frontiers in the Diagnosis of Hematological Malignancies
Monday, December 8, 2025, 2:45 p.m. - 4:00 p.m.
OCCC - W230
The rapid and accurate diagnosis of acute
leukemias remains a significant challenge in hematopathology. Traditional
diagnostic methods often fall short in providing timely and precise
classification, which is crucial for effective treatment planning. Recent
advancements in next-generation and third-generation sequencing technologies
have revolutionized our ability to read out nucleotide sequences and epigenetic
modifications, such as chromatin accessibility and DNA methylation. These
technologies offer a promising avenue for improving the diagnostic accuracy and
speed for hematological malignancies.
By leveraging long-read sequencing and
chromatin analysis, researchers are now able to classify leukemias more
accurately and rapidly than ever before. These innovative approaches enhance
our understanding of the molecular underpinnings of these malignancies and are
entering evaluation in clinical trials.
This session will highlight cutting-edge developments in epigenomic and chromatin-based diagnostics.
Chair:
Bert Van der Reijden, PhD
Radboudumc
Nijmegen, Netherlands
Speakers:
Volker Hovestadt, PhD
Dana-Farber Cancer Institute
Boston, MA, United States
Long-Read Epigenomic Classification of Acute Leukemia
Florence Nguyen-Khac
Hopital Pitie-Salpetriere, Sorbonne Universite
Paris, France
Chromatin-Based Diagnosis in Lymphocytic Leukemia
The Issue of Rejection of Allogeneic Cellular Therapies: Evidence, Mechanisms, and Novel Strategies to Overcome It
Sunday, December 7, 2025, 4:30 p.m. - 5:45 p.m.
OCCC - Sunburst Room (W340)
Allogeneic cell therapies offer significant advantages over autologous approaches, including reduced production times and broader accessibility for patients with rapidly progressing malignancies. However, immune rejection remains a critical challenge, as the host immune system often identifies and eliminates donor-derived cells through both adaptive and innate mechanisms. To address these barriers, researchers are developing innovative strategies such as genetic engineering to delete major histocompatibility complex molecules, overexpress immune checkpoint ligands, and disrupt key signaling pathways in innate immune cells. Additionally, immune cloaking techniques, like expressing CD47 to inhibit macrophage-mediated phagocytosis, and advancements in genome editing technologies, including CRISPR-Cas9, are being explored to enhance the persistence and efficacy of allogeneic cells.
This session will explore the breakthroughs aimed at overcoming immune rejection in allogeneic cell therapies.
Speakers:
Marco Ruella Jr, MD
Abramson Cancer Center
Philadelphia, PA, United States
Current Clinical Evidence of Allogeneic Cellular Products Failure and Mechanisms
May Daher, MD
MD Anderson Cancer Center
Houston, TX, United States
Strategies to Reduce Immune Rejection of Off-the-Shelf Cell Therapies
Transcending Boundaries: Study of Ambiguous Lineage Acute Leukemia Unlocks Mysteries for All Leukemias
Monday, December 8, 2025, 4:30 p.m. - 5:45 p.m.
OCCC - W224CDGH
The most recent 2022 World Health
Organization and 2022 International Consensus Classification for myeloid
neoplasms and acute leukemia each provided detailed descriptions of the current
criteria for diagnosis of acute leukemia of ambiguous lineage and mixed
phenotype acute leukemia. There have been large analyses of molecular data
highlighting the breadth and heterogeneity of the individual patient samples,
and literature defining the hematopoietic stem/progenitor cell as the cell of
origin.
These analyses have led to new genes and pathways that can be targeted with therapeutic intent. This session will provide an overview of cell lineage leading to acute leukemias and will highlight possible novel targets.
Speakers:
Catherine Smith, MD
University of California at San Francisco
San Francisco, CA, United States
Multi-omic Analysis Reveals the Heterogeneity and Stem Cell Origin of Acute Leukemia of Ambiguous Lineage/Mixed Phenotype Acute Leukemia
Ruud Delwel
Erasmus MC Cancer Institute and Oncode Institute
Rotterdam, Netherlands
Epigenetic Dysregulation Drives Mixed Phenotype Acute Leukemia
Scientific Symposia
Discovering the Biology of Hematopoiesis Through Studies of Bone Marrow Failure Syndromes
Saturday, December 6, 2025, 2:00 p.m. - 3:15 p.m.
Hyatt - Plaza Int'l HIJK
Studies exploring the germline genetic
causes of inherited bone marrow failure syndromes (IBMFS) provide important
opportunities to understand the mechanisms of normal and abnormal
hematopoiesis. This session will feature the latest studies using IBMFS as
models to identify the cellular and molecular underpinnings of hematopoiesis.
Fundamental insight into abnormal ribosome
biogenesis and the tissue specific phenotypes of human ribosomopathies will be
discussed, using the selective defects in erythropoiesis in Diamond-Blackfan
anemia syndrome as a model. Attendees will be updated on the connections
between aberrations in telomere biology genes associated with bone marrow
failure and telomere function in hematopoiesis. Updates on new mechanisms by
which genotoxic aldehydes contribute to aging phenotypes in Fanconi anemia will
be presented, with implications for understanding the link between hematopoiesis
and aging and its relevance to cancer development.
Taken together, this session will show how lessons from IBMFS can be translated to stem cell biology, aging and cancer.
Chair:
Austin G. Kulasekararaj, MD,MBBS,FRCPath,MRCP
King’s College Hospital
London, United Kingdom
Speakers:
Deena Iskander
Imperial
London, United Kingdom
The Role of Ribosome Dysregulation in Erythropoiesis
Luis Batista
Washington University School of Medicine
St Louis, MO, United States
The Connections Between Telomere Biology and Hematopoiesis
Meng Wang
Cornell University
Ithaca, NY, United States
Aldehyde-Induced DNA Damage in HSC Exhaustion and Aging: Lessons from Fanconi Anemia
Hematopoiesis in the Golden Years: Aging, Epigenetic Landscapes, and Clonal Destiny
Monday, December 8, 2025, 10:30 a.m. - 11:45 a.m.
OCCC - W312
Chronological age is the strongest risk factor for blood-borne disease, yet the mechanisms that link aging to disordered hematopoiesis are only now coming into focus. This session brings together niche biology, cutting-edge single-cell technologies and innate immune signaling to illuminate how the hematopoietic system changes across the lifespan and how those changes might be reversed. Together, the talks chart a coherent path from niche-encoded cues to immune-metabolic checkpoints and quantitative clonal readouts, highlighting emerging therapeutic strategies to reset aging hematopoiesis.
Dr. Marta Derecka will focus on the bone marrow microenvironment. Using EBF1 as an exemplar hematopoietic transcription factor expressed in stromal cells, she will dissect how mesenchymal niche programs shape steady-state hematopoiesis and how EBF1 dysregulation contributes to myeloproliferative neoplasm–associated fibrosis. These insights underscore that age-related hematopoietic decline is not solely cell-intrinsic but co-authored by the niche.
Dr. Leif Ludwig will explore clonal dynamics through the lens of mitochondrial DNA (mtDNA) mosaicism. Leveraging >1.25 million single-cell mutational profiles across age groups, longitudinal sampling, and post-transplant settings, mtDNA variants serve as natural barcodes to quantify human hematopoietic clones. Attendees will learn how clonally informative mtDNA mutations accumulate with age, how homeostatic clones remain largely stable yet regenerate dynamically after perturbation, and why apparent lineage “bias” often reflects immune expansions rather than fixed stem-cell programs until advanced age or clonal hematopoiesis tip the balance.
Dr. Eirini Trompouki will examine aging as an inflammatory and proteostatic phenotype governed by the innate RNA sensor MDA5. Genetic attenuation of MDA5 in mice preserves hematopoietic stem cell (HSC) quiescence, dampens inflammaging, improves metabolic fitness, and enhances repopulation capacity. Mechanistic data denote the master of proteostasis, HSF1, as an upstream node connecting MDA5 signaling to aging hallmarks, with small-molecule modulation of HSF1 reversing key phenotypes. This work positions antiviral sensing as actionable levers to delay HSC aging.
Chair:
Stephanie Halene
Yale University School of Medicine
New Haven, CT, United States
Speakers:
Marta Derecka, PhD
St. Jude Children's Research Hospital
Memphis, TN, United States
Context Matters: HSC Regeneration in the Cellular Niche
Leif S. Ludwig
Berlin Institute of Health at Charité Universitätsmedizin Berlin
Berlin, Germany
Mitochondrial DNA Mosaicism and Clonality in Human Hematopoiesis
Eirini Trompouki
Institute for Research on Cancer and Aging of Nice (IRCAN), CNRS UMR7284, INSERM U1081, Université Cote d'Azur,
Nice, France
Preventing Fires: Targeting Strategies to Mitigate Clonal Evolution
Ouch-it Hurts: Mechanisms of the Origin, Perception and Evolution of Pain in Sickle Cell Disease
Saturday, December 6, 2025, 2:00 p.m. - 3:15 p.m.
OCCC - W308
The understanding and treatment of pain in
many genetically inherited red blood cell disorders such as sickle cell disease
(SCD) and hemophilia remain understudied, while individuals with these rare
diseases continue to suffer and lead a poor quality of life since childhood.
Individuals with SCD suffer with debilitating and often life-threatening and
unpredictable episodes of acute pain of “crises,” in addition to lifelong
chronic pain. Opioids are the mainstay of pain therapy but remain challenging
due to side effects and stigma. A critical unmet need is to identify how organ
damage, sickle cell pathobiology, social determinants of health, and curative
therapies influence SCD pain?
This session will present the current understanding of mechanisms underlying sickle cell pain, revealing treatable targets for the development of novel interventions to prevent/treat pain. It will highlight novel molecular and cellular mechanism based pharmacologic and integrative approaches and advancement in non-invasive technology to treat pain with potential for translation to the clinics.
Chair:
Hyacinth Hyacinth
University of Cincinnati College of Medicine
Cincinnati, OH, United States
Speakers:
Kalpna Gupta, PhD
University of California, Irvine, CA
Orange, CA, United States
Two Sides of the Same Coin: Sickle Cell Pathobiology and Neural Mechanisms that Evoke, Maintain and Perceive Pain
Bin He
Carnegie Mellon University
Pittsburgh, PA, United States
Treat the Pain in My Brain: Understanding Neuromodulation and Technology Enhanced Interventions for Sickle Cell Disease Pain
Jahnavi Gollamudi, MD
University of Cincinnati
Cincinnati, OH, United States
It Refuses to Leave: The Challenging Bone Pain in Sickle Cell Disease
Special Symposium on the Basic Science in Hemostasis and Thrombosis
Monday, December 8, 2025, 4:30 p.m. - 6:00 p.m.
OCCC - Valencia Room W415D
Wound healing is a highly coordinated process composed of distinct but interdependent phases: hemostasis, inflammation, proliferation, and tissue remodeling. The precise timing of each phase is essential for effective tissue repair and the prevention of excessive scarring. This session will highlight the critical contributions of platelets, the coagulation cascade, and the fibrinolytic system in promoting optimal cutaneous wound healing.
The session will also explore the intricate mechanisms that regulate clot structure and influence wound healing at the intersection of hemostasis, vascular biology, and platelet function.
If you are attending the meeting in Orlando, following this session, please join ASH leadership and your colleagues at the ASH Networking Reception for the Hemostasis and Thrombosis Community, taking place just outside the room in the Valencia Lobby, from 6:00 p.m. - 7:30 p.m.
Speakers:
Ashley Brown
North Carolina State University
Raleigh, NC, United States
Clots, Cuts, and Healing: The Dynamic trio of Coagulation, Platelets, and Fibrinolysis
Tirthadipa Pradhan-Sundd, PhD
Versiti Blood Research Institute
Milwaukee, WI, United States
Blood, Clots, and Scars: Unraveling the Hidden Links Between Coagulation and Liver Cirrhosis
Targeting Cancer Metabolism – Innovative Methods to Translation
Monday, December 8, 2025, 2:45 p.m. - 4:00 p.m.
OCCC - W312
Cancer cells exhibit heightened
context-specific metabolism, driven in part by specific genetic lesions
(translocations/mutations) and microenvironmental constraints. Intrinsic tumor
metabolism has profound implications on therapy sensitivity and resistance.
Despite identification of small molecule metabolic inhibitors, targeting
metabolism has been challenging given the plasticity of cellular metabolism and
toxicity in normal cells. Testing metabolic inhibitors more comprehensively in
immune competent models and identification of synthetically lethal strategies
can overcome barriers to targeting cancer metabolism. A re-interest in tumor
metabolism has emerged from a better understanding of why cells engage aerobic
glycolysis i.e. the Warburg effect and identification of oncometabolites like
2-HG. Serum metabolites including 2-HG have aided in stratifying AML prognosis.
Diet and microbial derived metabolites also are emerging as important
regulators of therapy sensitivity.
This session will review mechanisms of tumor-specific metabolism, and insights on how extrinsic metabolites impact therapy sensitivity and resistance will be highlighted. The session will also shed light on approaches that have informed researchers’ understanding of cancer metabolism including the identification of therapeutic strategies for heme malignancies.
Chair:
Mala Shanmugam
Winship Cancer Institute, Emory University
Atlanta, GA, United States
Speakers:
Matthew Vander Heiden, MD, PhD
Massachusetts Institute of Technology
Cambridge, MA, United States
Nutrient Environment Considerations for Understanding Leukemia Therapy
Jeffrey C Rathmell
University of Chicago
Chicago, IL, United States
Metabolic Sources of Immune Cell Dysfunction
Andrew Intlekofer
Memorial Sloan Kettering Cancer Center
New York, NY, United States
Enzyme Hyperactivation to Target Oncometabolism
ASH Studio
A Holistic Approach: The Sickle Cell Foundation of Georgia, Inc. & The Sickle Cell Sanctuary
| Sunday, December 7, 2025 1:30 p.m. - 2:00 p.m. OCCC - Hall C ASH Studio Monday, December 8, 2025 8:30 a.m. - 9:00 a.m. OCCC - Hall C ASH Studio |
As part of our commitment to excellence through expansion and inclusion, the American Society of Hematology (ASH) is offering the ASH Treating Fairly Talks. This inclusive space is designed to help attendees recognize the drivers of differing outcomes for various populations as viewed through the hematology lens and provide tools to make changes in their institutions. These sessions will include a short expert commentary followed by facilitated conversations about actions that can be taken to drive change at your institution. The Treating Fairly Talks will take place at the ASH Studio, located in ASH Central (Orange County Convention Center, West Hall C).
Ms. Tabatha McGee, CEO of the Sickle Cell Foundation of Georgia, Inc., will present on successful community-centric initiatives for sickle cell disease. back to topBreaking Barriers in Blood Cancer: Transforming Access and Outcomes Across Populations
| Sunday, December 7, 2025 11:00 a.m. - 11:30 a.m. OCCC - Hall C ASH Studio Monday, December 8, 2025 12:00 p.m. - 12:30 p.m. OCCC - Hall C ASH Studio |
As part of our commitment to excellence through expansion and inclusion, the American Society of Hematology (ASH) is offering the ASH Treating Fairly Talks. This inclusive space is designed to help attendees recognize the drivers of differing outcomes for various populations as viewed through the hematology lens and provide tools to make changes in their institutions. These sessions will include a short expert commentary followed by facilitated conversations about actions that can be taken to drive change at your institution. The Treating Fairly Talks will take place at the ASH Studio, located in ASH Central (Orange County Convention Center, West Hall C).
Dr. Tina Bhatnagar will present on the impact of geography on care. back to topBreaking Financial Barriers to Care Through Affordable Innovation
| Saturday, December 6, 2025 3:30 p.m. - 4:00 p.m. OCCC - Hall C ASH Studio Monday, December 8, 2025 1:00 p.m. - 1:30 p.m. OCCC - Hall C ASH Studio |
As part of our commitment to excellence through expansion and inclusion, the American Society of Hematology (ASH) is offering the ASH Treating Fairly Talks. This inclusive space is designed to help attendees recognize the drivers of differing outcomes for various populations as viewed through the hematology lens and provide tools to make changes in their institutions. These sessions will include a short expert commentary followed by facilitated conversations about actions that can be taken to drive change at your institution. The Treating Fairly Talks will take place at the ASH Studio, located in ASH Central (Orange County Convention Center, West Hall C).
Dr. Andres Gomez-De Leon will present on the financial factors to accessing care.
back to topClassical Hematology Advancement Mentorship Program (CHAMP)
| Sunday, December 7, 2025, 8:30 a.m. - 9:00 a.m. OCCC - Hall C ASH Studio |
The ASH Studio hosts brief, targeted talks that focus on removing barriers to high-quality care, principles of medical education, and cutting-edge teaching techniques. These sessions will take place at the ASH Studio, located in ASH Central (Orange County Convention Center, West Hall C).
back to topFrom Precision Medicine to Personalized Care: Meeting Patients Where They Are
| Saturday, December 6, 2025 1:30 p.m. - 2:00 p.m. OCCC - Hall C ASH Studio Sunday, December 7, 2025 9:00 a.m. - 9:30 a.m. OCCC - Hall C ASH Studio |
As part of our commitment to excellence through expansion and inclusion, the American Society of Hematology (ASH) is offering the ASH Treating Fairly Talks. This inclusive space is designed to help attendees recognize the drivers of differing outcomes for various populations as viewed through the hematology lens and provide tools to make changes in their institutions. These sessions will include a short expert commentary followed by facilitated conversations about actions that can be taken to drive change at your institution. The Treating Fairly Talks will take place at the ASH Studio, located in ASH Central (Orange County Convention Center, West Hall C).
Dr. Eneida Nemecek will present on tailoring care for optimal patient outcomes.
back to topImpact of Geography on Care
| Saturday, December 6, 2025 11:00 a.m. - 11:30 a.m. OCCC - Hall C ASH Studio Monday, December 8, 2025 10:00 a.m. - 10:30 a.m. OCCC - Hall C ASH Studio |
As part of our commitment to excellence through expansion and inclusion, the American Society of Hematology (ASH) is offering the ASH Treating Fairly Talks. This inclusive space is designed to help attendees recognize the drivers of differing outcomes for various populations as viewed through the hematology lens and provide tools to make changes in their institutions. These sessions will include a short expert commentary followed by facilitated conversations about actions that can be taken to drive change at your institution. The Treating Fairly Talks will take place at the ASH Studio, located in ASH Central (Orange County Convention Center, West Hall C).
Dr. Norma Ada will present on the impact of geography on care.
back to topInnovative Teaching Approaches for Adult Learning
| Monday, December 8, 2025, 12:
30 p.m. - 1:00 p.m. OCCC - Hall C ASH Studio |
The ASH MedEd Talks are targeted talks that focus on removing barriers to high-quality care, principles of medical education, and cutting-edge teaching techniques. These sessions will take place at the ASH Studio, located in ASH Central (Orange County Convention Center, West Hall C).
back to topOnline Hematology Curriculum/Podcast
| Sunday, December 7, 2025, 11:
30 a.m. - 12:00 p.m. OCCC - Hall C ASH Studio |
The ASH MedEd Talks are targeted talks that focus on removing barriers to high-quality care, principles of medical education, and cutting-edge teaching techniques. These sessions will take place at the ASH Studio, located in ASH Central (Orange County Convention Center, West Hall C).
back to topPromoting Language Equity in Care and Research
| Saturday, December 6, 2025 9:00 a.m. - 9:30 a.m. OCCC - Hall C ASH Studio Sunday, December 7, 2025 4:00 p.m. - 4:30 p.m. OCCC - Hall C ASH Studio |
As part of our commitment to excellence through expansion and inclusion, the American Society of Hematology (ASH) is offering the ASH Treating Fairly Talks. This inclusive space is designed to help attendees recognize the drivers of differing outcomes for various populations as viewed through the hematology lens and provide tools to make changes in their institutions. These sessions will include a short expert commentary followed by facilitated conversations about actions that can be taken to drive change at your institution. The Treating Fairly Talks will take place at the ASH Studio, located in ASH Central (Orange County Convention Center, West Hall C).
Dr. Alisa Khan will present on the importance of language on outcomes of care.
ASH Wellness Studio
Brain-Boosting Break
| Saturday, December 6, 2025 11:35 a.m. - 11:45 a.m. OCCC – Hall C Wellness Studio Sunday, December 7, 2025 11:20 a.m. - 11:30 a.m. OCCC – Hall C Wellness Studio |
Enhance mental health & performance with this research-proven ancient practice! This session will take place at the ASH Wellness Studio, located in ASH Central (Orange County Convention Center, West Hall C).
Speaker:
Kulvinder Kaur
Infinity Wellness Partners
Carlsbad,
CA, United States
Center Yourself
| Saturday, December 6, 2025 1:45 p.m. - 1:55 p.m. OCCC – Hall C Wellness Studio Sunday, December 7, 2025 4:15 p.m. - 4:25 p.m. OCCC – Hall C Wellness Studio |
Calm the mind & reconnect with the present moment when experiencing stress! This session will take place at the ASH Wellness Studio, located in ASH Central (Orange County Convention Center, West Hall C).
Speaker:
Jesse Lewis
Infinity Wellness Partners
Washington,
DC, United States
Emotional Freedom Technique
| Saturday, December 6, 2025 11:20 a.m. - 11:30 a.m. OCCC – Hall C Wellness Studio Sunday, December 7, 2025 11:35 a.m. - 11:45 a.m. OCCC – Hall C Wellness Studio Monday, December 8, 2025 12:05 p.m. - 12:15 p.m. OCCC – Hall C Wellness Studio |
Manage emotionally-charged moments discreetly, quickly, & effectively! This session will take place at the ASH Wellness Studio, located in ASH Central (Orange County Convention Center, West Hall C).
Speaker:
Kulvinder Kaur
Infinity Wellness Partners
Carlsbad,
CA, United States
Happy Hands and Wrists
| Monday, December 8, 2025, 10:
15 a.m. - 10:25 a.m. OCCC – Hall C Wellness Studio |
Try these tiny, yet terrific tweaks to shortcut hand & wrist strain! This session will take place at the ASH Wellness Studio, located in ASH Central (Orange County Convention Center, West Hall C).
Speaker:
Krystol Hines
Infinity Wellness Partners
District Heights,
MD, United States
Movement Bites
| Saturday, December 6, 2025, 3:45 p.m. - 3:55 p.m. OCCC – Hall C Wellness Studio |
Re-energize your body & reboot your mind with 1-minute of motion! This session will take place at the ASH Wellness Studio, located in ASH Central (Orange County Convention Center, West Hall C).
Speaker:
Jesse Lewis
Infinity Wellness Partners
Washington,
DC, United States
Plug Into Nature
| Saturday, December 6, 2025 3:35 p.m. - 3:45 p.m. OCCC – Hall C Wellness Studio Monday, December 8, 2025 2:35 p.m. - 2:45 p.m. OCCC – Hall C Wellness Studio |
Step away from your screen & plug into the power of the great outdoors! This session will take place at the ASH Wellness Studio, located in ASH Central (Orange County Convention Center, West Hall C).
Speaker:
Jesse Lewis
Infinity Wellness Partners
Washington,
DC, United States
Reignite Your Resilience
| Sunday, December 7, 2025 11:05 a.m. - 11:15 a.m. OCCC – Hall C Wellness Studio Monday, December 8, 2025 12:20 p.m. - 12:30 p.m. OCCC – Hall C Wellness Studio |
Experience more clarity & resilience during the workday in a few slow, deep breaths! This session will take place at the ASH Wellness Studio, located in ASH Central (Orange County Convention Center, West Hall C).
Speaker:
Kulvinder Kaur
Infinity Wellness Partners
Carlsbad,
CA, United States
Reset Your Posture
| Saturday, December 6, 2025 9:15 a.m. - 9:25 a.m. OCCC – Hall C Wellness Studio Monday, December 8, 2025 10:05 a.m. - 10:15 a.m. OCCC – Hall C Wellness Studio |
Discover the secret microbreak of perfecting your posture! This session will take place at the ASH Wellness Studio, located in ASH Central (Orange County Convention Center, West Hall C).
Speaker:
Krystol Hines
Infinity Wellness Partners
District Heights,
MD, United States
Shake It Off
| Monday, December 8, 2025, 12:
35 p.m. - 12:45 p.m. OCCC – Hall C Wellness Studio |
Release pent-up tension & heavier emotions to lift your mood in seconds! This session will take place at the ASH Wellness Studio, located in ASH Central (Orange County Convention Center, West Hall C).
Speaker:
Jesse Lewis
Infinity Wellness Partners
Washington,
DC, United States
Snacks For Better Fuel
| Saturday, December 6, 2025 1:35 p.m. - 1:45 p.m. OCCC – Hall C Wellness Studio Sunday, December 7, 2025 4:05 p.m. - 4:15 p.m. OCCC – Hall C Wellness Studio |
Learn how & when to make healthy snacking the easy, fast, & tasty choice! This session will take place at the ASH Wellness Studio, located in ASH Central (Orange County Convention Center, West Hall C).
Speaker:
Jesse Lewis
Infinity Wellness Partners
Washington,
DC, United States
Sneaky Ways to Move More
| Sunday, December 7, 2025, 9:05 a.m. - 9:15 a.m. OCCC – Hall C Wellness Studio |
Enjoy these 30-second, disguised exercises for a busy workday! This session will take place at the ASH Wellness Studio, located in ASH Central (Orange County Convention Center, West Hall C).
Speaker:
Krystol Hines
Infinity Wellness Partners
District Heights,
MD, United States
The Chair Check
| Saturday, December 6, 2025 9:05 a.m. - 9:15 a.m. OCCC – Hall C Wellness Studio Sunday, December 7, 2025 9:15 a.m. - 9:25 a.m. OCCC – Hall C Wellness Studio |
Sit smarter with this 1-minute activity designed to decompress the lower back! This session will take place at the ASH Wellness Studio, located in ASH Central (Orange County Convention Center, West Hall C).
Speaker:
Krystol Hines
Infinity Wellness Partners
District Heights,
MD, United States
The Typing Timeout
| Saturday, December 6, 2025, 11:
05 a.m. - 11:15 a.m. OCCC – Hall C Wellness Studio |
A stretching sequence to loosen the upper body when doing computer work! This session will take place at the ASH Wellness Studio, located in ASH Central (Orange County Convention Center, West Hall C).
Speaker:
Krystol Hines
Infinity Wellness Partners
District Heights,
MD, United States